Surveillance and Response to Highly Pathogenic Avian and Pandemic Influenza in the Libyan Arab Jamahiriya, 57955-57966 [E6-16181]
Download as PDF
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
Dated: September 26, 2006.
Sandra R. Manning,
Deputy Director for Operations, Office of
Global Health Affairs, U.S. Department of
Health and Human Services.
[FR Doc. E6–16178 Filed 9–29–06; 8:45 am]
BILLING CODE 4150–38–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Surveillance and Response to Highly
Pathogenic Avian and Pandemic
Influenza in the Libyan Arab
Jamahiriya
Office of Global Health Affairs,
Office of the Secretary, DHHS.
ACTION: Notice.
rmajette on PROD1PC67 with NOTICES1
AGENCY:
Announcement Type: Single
Eligibility—FY 2006 Initial
Announcement.
Funding Opportunity Number: OGHA
06–025.
GSA Catalog of Federal Domestic
Assistance: 93. 283.
DATES: October 2, 2006: Application
Availability.
October 10, 2006: Optional Letter of
Intent due by 5 p.m. ET.
October 17, 2006: Application due by
5 p.m. ET.
October 27, 2006: Award date.
SUMMARY: An influenza pandemic has
greater potential than any other
naturally occurring infectious disease to
cause large and rapid global and
domestic increases in death and serious
illness. Preparedness is the key to
substantially reducing the health, social,
and economic impacts of an influenza
pandemic and other public-health
emergencies.
On November 1, 2005, President
George W. Bush announced the U.S.
National Strategy for Pandemic
Influenza and the following day,
Secretary Michael O. Leavitt released
the HHS Pandemic Influenza Plan. One
of the primary objectives of both
documents is to leverage global
partnerships to increase preparedness
and response capabilities around the
world with the intent of stopping,
slowing, or otherwise limiting the
spread of a pandemic to the United
States.1 Pillars Two and Three of the
National Strategy set out the clear goals
of ensuring the rapid reporting of
outbreaks and containing outbreaks
beyond the borders of the United States,
by taking the following actions:
• Working through the International
Partnership on Avian and Pandemic
Influenza, as well as through other
1 National
Stragegy for Pandemic Influenza, p. 2.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
political and diplomatic channels, such
as the United Nations and the AsiaPacific Economic Cooperation Forum, to
ensure transparency, scientific
cooperation, and the rapid reporting of
highly pathogenic avian and human
influenza cases;
• Supporting the development of the
proper scientific and epidemiological
expertise in affected regions to ensure
the early recognition of changes in the
pattern of highly pathogenic avian or
human influenza outbreaks;
• Supporting the development and
maintenance of sufficient host-country
laboratory capacities and diagnostic
reagents in affected regions, to provide
rapid confirmation of cases of influenza
in animals and humans;
• Working through the International
Partnership to develop a coalition of
strong partners to coordinate
containment efforts, that is, actions to
limit the spread of an influenza with
pandemic potential beyond where it is
first located; and,
• Providing guidance to all levels of
Government in affected nations on the
range of options for riskcommunication, infection-control, and
containment.
We rely upon our international
partnerships, with the United Nations
(UN); international organizations; and
private and non-profit organizations, to
amplify our efforts, and will engage
them on a multilateral and bilateral
basis. Our international effort to contain
and mitigate the effects of an outbreak
of pandemic influenza is a central
component of our overall strategy. In
many ways, the character and quality of
the U.S. response and that of our
international partners could play a
determining role in the severity of a
pandemic.
The International Partnership on
Avian and Pandemic Influenza,
launched by President Bush at the UN
General Assembly in September 2005,
stands in support of multinational
organizations and national
Governments. Members of the
Partnership have agreed that the
following ten principles will guide their
efforts:
1. International cooperation to protect
the lives and health of our people;
2. Timely and sustained, high-level,
global, political leadership to combat
avian and pandemic influenza;
3. Transparency in reporting of
influenza cases in humans and in
animals caused by virus strains that
have pandemic potential, to increase
understanding and preparedness, and
especially to ensure rapid and timely
response to potential outbreaks;
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
57955
4. Immediate sharing of
epidemiological data and samples with
the World Health Organization (WHO)
and the international community to
detect and characterize the nature and
evolution of any outbreaks as quickly as
possible, by using, where appropriate,
existing networks and mechanisms;
5. Rapid reaction to address the first
signs of accelerated transmission of
H5N1 and other highly pathogenic
influenza strains, so appropriate
international and national resources can
be brought to bear;
6. Prevent and contain an incipient
epidemic through capacity-building and
in-country collaboration with
international partners;
7. Work in a manner complementary
to and supportive of expanded
cooperation with and appropriate
support of key multilateral
organizations (including WHO, Food
and Agriculture Organization, and the
World Organization for Animal Health);
8. Timely coordination of bilateral
and multilateral resource allocations;
dedication of domestic resources
(human and financial); improvements in
public awareness; and development of
economic and trade contingency plans;
9. Increased coordination and
harmonization of preparedness,
prevention, response, and containment
activities among nations,
complementing domestic and regional
preparedness initiatives and
encouraging, where appropriate, the
development of strategic regional
initiatives; and,
10. Actions based on the best
available science.
Through the Partnership and other
bilateral and multilateral initiatives, we
will promote these principles and
support the development of an
international capacity to prepare for,
detect, and respond to an influenza
pandemic.
Following the President’s National
Strategy, this announcement seeks to
support selected foreign Governments
through their Ministries of Health or
other responsible Ministries for humanhealth or public-health emergency
preparedness.
Proposals may only include program
elements that fall within designated
areas under the Three Pillars of the U.S.
National Strategy assigned to the U.S.
Department of Health and Human
Services (HHS) as described below. This
support is meant to enhance, and not to
supplant, current influenza-surveillance
activities. Proposals should build upon
infrastructure already in place.
Preference will go to countries with
limited resources, where influenza
surveillance is not well-established, and
E:\FR\FM\02OCN1.SGM
02OCN1
57956
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
which have experienced outbreaks of
H5N1 influenza in animals or humans
or are judged at-risk of such outbreaks
by HHS and the WHO Secretariat. Only
the Ministry of Health of the Great
Socialist People’s Libyan Arab
Jamahiriya is eligible under this
announcement.
The term ‘‘containment’’ as used in
this announcement, warrants special
consideration. ‘‘Containment’’ here
refers to efforts to control the emergence
of a new influenza virus with pandemic
potential and high pathogenicity that is,
a new influenza strain efficiently
transmitted among humans and causes
severe disease in a high proportion of
infected persons. The goal of
containment would be to identify the
first outbreak with such a strain, and to
apply a coordinated, integrated,
intensive public-health response to
interrupt transmission among humans.
(Severe Acute Respiratory Syndrome,
for example, was ultimately contained
after it spread to a number of countries.)
A principle intent of this announcement
is to assist partner countries to build
capacity for identification, investigation
and containment of such a strain.
Pillar III. Response and Containment
1. Local rapid-response teams; and,
2. Infection control in public health-care
settings.
infrastructure. The uncertainty of the
course of a pandemic and unknown
scientific factors, as well as unforeseen
and unintended outcomes with respect
to Governmental actions and statements
make this a communicationsmanagement issue of formidable
proportion. The economic and societal
effects of such a pandemic could have
a significant detrimental impact on a
nation and its people.
A critical component of national
preparedness for an influenza pandemic
is informing the public about this
potential threat and providing a solid
foundation of information upon which
to base future actions. To be effective,
Governments should base these
strategies on scientifically derived riskcommunications principles that are
critical before, during, and after an
influenza pandemic. Effective
communication guides the public, the
news media, health-care providers, and
other groups in responding
appropriately to outbreak situations and
adhering to public-health measures.
These guidelines must be an integral
part of a national pandemic plan as
developed and coordinated by a nation’s
appropriate agencies, such as Ministries
of Health, Agriculture, Trade,
Information, and Tourism.
Public-health and health-care workers
will be the first to observe and report
suspicious clusters of respiratory
disease, and could also be the most
trusted resources of information for the
populations they serve. Therefore, these
audiences must be a specific target for
health-communications marketing and
strategy. Communication strategies
should include formative evaluation,
message development and testing, and
summative evaluation.
In addition, these critical audiences
will be integral to any national
response. Yet, worksite restrictions may
hamper efforts to receive and provide
validated up-to-date information (lack of
computers, Internet access,
quarantining, etc.). A mechanism for the
rapid dissemination of information both
to national and District or Provincial
health-response units and international
partners is necessary.
To build trust and assure that
information flows through common
channels of communication,
coordination of media messages,
training of journalists and development
of credible national Government
spokespeople is also recommended.
Pillar One
Pandemic influenza presents a
massive communications challenge to
all levels of a nation’s Government as
well as its society, economy, and critical
Pillar Two
One component of pandemic
preparedness involves understanding
the impact annual epidemics of
influenza have on a population. Data
Pillar I. Preparedness and Communication
1. National Government Public-Health
Preparedness Plans, Policy, and
Coordination; and,
2. Communications:
(a) Targeting health care workers (HCW);
and,
(b) National Government spokespersons
and risk messages.
rmajette on PROD1PC67 with NOTICES1
Pillar II. Surveillance and Detection
1. Laboratory capacity and infrastructure
for virologic surveillance;
2. Epidemiology capacity and
infrastructure for disease surveillance;
3. Sentinel, laboratory-based surveillance
for influenza-like illness (ILI) and/or
hospital-based surveillance for severe
disease; development or enhancement of an
in-country integrated (lab and epi)
surveillance network for influenza; and
4. Comprehensive, territory-wide
surveillance for cases and clusters of
suspicious respiratory and febrile illness that
could represent emerging new pandemics.
Note: Components 3 and 4 have distinct
operational requirements, but awardees must
fully integrate them into one overall, multidisciplinary surveillance network for
influenza.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
regarding impact are critical to the
development of prevention and control
measures, such as vaccination policies.
Vaccination efforts are the cornerstone
of influenza prevention, and will be the
primary means of mitigating the impact
of an influenza pandemic, when we
have a vaccine proven safe and effective
against the pandemic strain. Another
critical area for preparedness is the
ability to identify potential human cases
of novel influenza strains, so national
Governments and the international
community can launch early efforts to
attempt to stop outbreaks.
The systematic collection of
influenza-surveillance data over time is
necessary to monitor and track the
activity of influenza virus and disease,
and is essential to understanding the
impact influenza has on a country’s
population. Developing influenzasurveillance networks is critical for the
rapid detection of new variants,
including those with pandemic
potential, to contribute to the global
disease-surveillance system. Global
collaboration, under the coordination of
the Secretariat of the World Health
Organization (WHO), is a key feature of
influenza surveillance.
The WHO established an international
laboratory-based surveillance network
for influenza in 1948, which currently
consists of 113 National Influenza
Center (NIC) laboratories in 84
countries, and four WHO Collaborating
Centers for Reference and Research of
Influenza (including one located at the
HHS Centers for Disease Control and
Prevention [CDC]). The primary
purposes of the WHO network are to
detect the emergence and spread of new
antigenic variants of influenza, to use
this information to update the
formulation of annual human influenza
vaccine, and to provide as much
warning as possible about the next
pandemic. This system provides the
foundation of worldwide influenza
prevention and control, and is a critical
contribution to preserving global health
security.
Monitoring of human and animal
influenza viruses and providing
contributions to the global diseasesurveillance system, including the
sharing of appropriate specimens and
viral isolates, will assure the data used
in the WHO Secretariat’s annual vaccine
recommendations are relevant to each
country that participates. Increased
participation in the global surveillance
system for influenza viruses will
enhance each country’s ability to
monitor severe respiratory illness, to
develop vaccine policy for influenza,
and to help build global and regional
strategies for the prevention and control
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
of influenza in animals and humans.
Monitoring the disease activity of
influenza is important to facilitate
planning for the allocation of resources,
appropriate and clear communications
with the public, containment and
response interventions, and outbreak
investigations.
rmajette on PROD1PC67 with NOTICES1
Pillar Three
In the absence of available vaccine or
specific antiviral treatment, infection
control and related non-pharmaceutical
public-health interventions are the
mainstay of reducing the spread and
impact of an influenza pandemic.
Correct and consistent infection-control
practices should be a part of routine
health-care delivery, an active
consideration in planning for pandemic
influenza and other infectious- disease
outbreaks, and an integral part of
outbreak response and control. The dual
goals of providing safe health-care to
patients and protecting health-care
personnel while they work are critical to
maintaining a functional health-care
system. Elements of health-care related
infection-control also influence
community guidance for self-protection
and the prevention of infection.
The principal intent of this assistance
is to support surveillance and response,
to allow for the containment of a highly
pathogenic virus transmissible among
humans. A second intent is to support
the development of epidemiologic,
laboratory, and related capacity to
detect, respond to, and monitor shifts in
influenza viruses, as well as in severe
respiratory illness syndromes. A third
intent is to help strengthen the
connection of national institutions,
especially National Influenza Centers, to
more fully participate in the WHO
Influenza Program, and be more capable
of sharing specimens and quality data of
the circulation of influenza viruses from
throughout the country.
Measurable outcomes of the program
will be in alignment with the three
Pillars of the HHS Pandemic Influenza
Operational Plan and the Pillars of the
President’s National Strategy for
Pandemic Influenza, the principles of
the International Partnership on Avian
and Pandemic Influenza, and the
following performance goal(s) for the
Office of Global Health Affairs (OGHA).
This announcement is only for nonresearch activities supported by HHS,
including OGHA. If an applicant
proposes research activities, HHS will
not review the application. For the
definition of ‘‘research,’’ please see the
HHS/CDC Web site at the following
Internet address: https://www.cdc.gov/
od/ads/opspoll1.htm.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
1.2
Recipient Activities
The proposal may include activities
under all three Pillars. However, the
application all of those activities should
prioritize the principal intent of rapidly
building epidemiologic, laboratory, and
response capabilities to contain an
emergent, highly pathogenic virus
transmissible among humans.
Applicants should allocate a minimum
of 70 percent of resources to Pillar Two
activities unless they present strong
evidence that the key capacities
represented in Pillar Two are already
well-established in the country, or can
be made such with less than 70 percent
of the resources for which applicants
have applied. Applicants can select
activities other than Pillar Two based on
the National Pandemic Plan. If
applicants do not propose any activities
for one or more Pillars, they must
describe a brief plan for how they will
address those activities, and must
describe the funding sources to
underwrite those activities, whether
national resources or financing from an
alternate partner or funding source.
Activities recipients may perform
under this program are as follows:
Pillar I Preparedness and
Communication
1.1 Preparedness Plans, Policy, and
Coordination
• Developing a high-level, InterMinisterial Task Force or working group
for influenza that meets regularly with
representation from both the humanand animal-health sectors, Government
Ministries, businesses, and nongovernmental organizations (NGOs); to
determine ways to improve national
influenza surveillance; develop
prevention and control measures such
as vaccine policy; and work on national
pandemic preparedness.
• Adhering to the core principles of
the International Partnership on Avian
and Pandemic Influenza (https://
www.state.gov/r/pa/prs/ps/2005/
53865.htm), including transparency and
rapid reporting of cases.
• Establishing a national plan, based
on scientifically valid information, for
containing influenza in animals with
human pandemic potential, and for
responding to a human pandemic.
• Testing and executing those plans.
• Committing to the timely
coordination of bilateral and
multilateral resource allocations, the
dedication of domestic resources
(human and financial), and the
development of contingency plans.
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
57957
Communications
• Establishing a communications
component as part of a National
Pandemic Plan, coordinated by the
Ministries of Health, Agriculture,
Information, Trade, Tourism, etc., as
appropriate to accomplish the
following:
• Establishing a communications
strategy to coordinate the development,
testing and evaluation of health
information among involved Ministries
and bilateral/multilateral agencies that
are providing assistance.
• Prepare public-health messages in
local languages to ask medical and
public-health workers to report unusual
cases of respiratory disease to local
authorities, by emphasizing that a
cluster of severe pneumonia of
unknown origin anywhere in the world
constitutes a potential international
emergency.
• Prompt reporting of cases and
clusters of human infection with avian
influenza A (H5N1) by doing the
following:
Æ Providing technical support for
local-language public-health education
and outreach efforts by Ministries of
Health and Agriculture, the World
Health Organization (WHO)/
Headquarters, and the relevant WHO
Regional Offices;
Æ Providing local-language training
for health-care providers in identifying
patients with risk factors for disease
caused by highly pathogenic avian
influenza A (H5N1); and,
Æ Supporting public-sector field staff
in Districts and Provinces in detecting
and reporting suspected cases of highly
pathogenic avian influenza.
• Develop public-health materials in
local languages for use in communitybased educational campaigns that
inform people about infection control
and public-health containment (or
‘‘social distancing’’) measures (e.g.,
quarantine, school closures, travel
restrictions) that can control outbreaks
of pandemic influenza. These materials
will also provide information about the
use of proper and safe antiviral drugs
and vaccines.
Æ Ensure these activities and
messages fit together and are consistent
with inter-Ministerial Governmental
social- mobilization efforts and similar
efforts funded by the U.S. Agency for
International Development (USAID) and
other donors.
• Develop local-language mass-media
and community-outreach programs that
promote AI awareness and behavior
change, if other partners are not
addressing this area consistent with the
national pandemic response plan.
E:\FR\FM\02OCN1.SGM
02OCN1
57958
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
• Identify and train credible national
Government spokespeople.
• Partner early with media editors
and journalists, if other partners are not
addressing this area, consistent with the
national pandemic response plan, to:
Æ Provide valid training on avian
influenza to journalists and editors.
• Develop public-health materials in
local languages that inform health-care
workers about infection-control
measures that can control the spread of
pandemic influenza in health-care
facilities and in the workplace. These
materials will also provide information
about antiviral use.
• Develop health-promotion and
education activities in local languages to
increase professional awareness of the
need to detect each and every case and
cluster of human respiratory infection
(family, health care, or institutional)
during the pandemic-alert period.
• Work with the WHO Secretariat and
other multilateral organizations, existing
bilateral programs, and private-sector
partners to develop workplace,
community- and hospital-based health
prevention, promotion, and education
activities.
Pillar II. Surveillance and Detection
2.1 Laboratory Capacity and
Infrastructure
• Train laboratory scientists and
technicians in proper laboratory
techniques for influenza detection,
typing, and sub-typing.
• Install and maintain laboratory
equipment and infrastructure needed to
carry out the functions of WHO-certified
National Influenza Center, if possible, or
work towards the capacity to carry out
those functions.
• Maintain and assure biosafety and
biosecurity of targeted laboratories
according to national and international
standards.
• Install and maintain informationmanagement equipment for reporting of
results from influenza laboratory work,
back to the sites providing specimens, to
national leaders, and to the WHO
Secretariat and other international
partners.
rmajette on PROD1PC67 with NOTICES1
2.2 Epidemiology Capacity and
Infrastructure
• Train epidemiologists at
appropriate levels and sufficient scale to
be able to support multiple surveillance,
outbreak investigation and response,
and disease-control activities involved
in avian and pandemic preparedness.
• Establish needed information and
data-management capacity and
telecommunications capacity needed for
surveillance, outbreak response, and
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
disease control, including containment
of a suspect pandemic virus.
• Establish other needed
infrastructure critical to supporting
outbreak detection, response, and
containment efforts.
2.3 Sentinel, Laboratory-Based
Surveillance for Influenza-Like Illnesses
and/or Hospital-Based Surveillance for
Severe Disease
• Develop a nationwide system to
collect virologic and epidemiologic data
for influenza, including appropriate
samples and viral isolates, by
establishing three or more sites with
good geographic distribution throughout
the country. Each site will consist of a
local laboratory and one or more public
or private clinics or hospitals from
which to collect data. Each site should
do the following:
Æ Conduct virologic and
epidemiologic surveillance for influenza
by collecting information, including
appropriate samples and specimens for
virus isolation year-round;
Æ Have lab capacity for performing
the isolation and typing of influenza
viruses; or at least molecular technology
for identification;
Æ Collect information on influenzalike illnesses and/or severe respiratory
disease at each site by building on
information already available. Possible
sources of information are the following:
(1) Recording visits by patients with
influenza-like-illness to physicians or
public or private primary-care clinics or
hospitals, based on a standard case
definition; (2) Monitoring hospital
admissions for severe respiratory illness
and pneumonia, based on a standard
case definition. The sites should collect
patient information, such as age, patient
history and other relevant information;
Æ Collect a subset of at least 10 (and
preferably up to 25) specimens from the
patient populations under surveillance
that exhibit febrile, acute upperrespiratory illness weekly during the
period of surveillance by using a
standard case definition (preferably one
established by the WHO Secretariat) and
submit them to the local laboratory for
the site;
Æ During unusual outbreaks of
influenza, such as outbreaks with
unusual epidemiologic characteristics,
or those related to infections by highly
pathogenic avian or other animal
influenza viruses; collect epidemiologic
information to characterize the
outbreak; and collect additional samples
for viral isolation, including tissue
samples, if appropriate; and submittal to
the site laboratory. Report the outbreak
to the National Influenza Center for
further transmittal to one or more of the
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
WHO-designated Collaborating Centers
for Influenza;
Æ Prepare and provide regular weekly
reports on the epidemiologic
information collected (influenza-likeillness and/or severe respiratory illness)
to the local laboratory and to the
National Influenza Center for further
transmittal to one or more of the WHOdesignated Collaborating Centers for
Influenza;
Æ If proper biosafety conditions exist,
perform viral isolation for influenza
viruses, either in tissue culture or in
eggs, type positive isolates for influenza
A and B, and, if possible, subtype
influenza viruses;
Æ Store original clinical materials at
¥70 degrees celsius, until the beginning
of the next influenza season; and,
Æ Submit viral isolates to the National
Influenza Center within the country on
at least a monthly basis for more
complete analysis.
• Each WHO-certified National
Influenza Center also will be
responsible for and commit to
performing the following activities:
Æ Performing preliminary antigenic
and, if possible, genetic characterization
on the virus isolates submitted from the
laboratories in the surveillance sites
(including those isolates grown at the
NIC);
Æ Send, as quickly as possible,
representative influenza virus isolates to
one of the four WHO Collaborating
Centers for Influenza, including any
low-reacting viruses, as tested by using
the WHO reagent kit, each month during
the period of surveillance and more
frequently, if possible;
Æ If any viruses are unsubtypable as
tested by using the WHO kit, alert the
WHO Secretariat and send the virus
isolate to one of the four WHO
Collaborating Centers for Influenza
immediately;
Æ During the period of surveillance,
provide weekly influenza-surveillance
information, preferably electronically to
the WHO Secretariat through FluNet;
Æ Provide an annual national
summary on influenza activity,
virological information, and other
relevant information on influenza to the
WHO Secretariat and the WHO
Collaborating Center for Influenza at
HHS/CDC;
Æ Provide technical expertise and
training to support the surveillance sites
and laboratories in the national network
in developing the capacity to type and
subtype viruses and when feasible to
identify avian influenza viruses by
molecular techniques; and provide
reagents to national public-health
laboratories as able;
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
rmajette on PROD1PC67 with NOTICES1
Æ Establish the capacity to identify
avian influenza viruses in specimens
collected from suspect cases using
molecular diagnostic techniques;
Æ Provide support for human-health
diagnostic laboratories in your network
by giving assistance in the development
and implementation of rapid laboratory
diagnostics protocols and methods, and
to establish objectives for rapid
screening; and,
Æ Establish linkages with surveillance
systems that detect influenza viruses in
animal populations and with national
Government authorities responsible for
animal health.
• Foreign Governments that apply for
funding through this announcement
should play a substantial role in the
development and support of the
influenza-surveillance network in their
countries, by committing to the
following:
Æ Timely and sustained high-level
political leadership to combat avian and
novel influenza strains;
Æ Complete transparency in the
reporting of influenza cases in humans
and animals caused by virus strains that
have pandemic potential;
Æ Timely sharing of influenzasurveillance information with the WHO
Global Influenza Surveillance network
by facilitating the regular exchange of
information and virus samples with one
of the four WHO Collaborating Centers
for Influenza; and,
Æ Providing continued support for
influenza activities within the country
and developing a plan for increased
participation in the global influenza
surveillance network over a five-year
period.
2.4 Comprehensive, National
Surveillance for Clusters and Cases of
Severe Respiratory and Febrile
Syndromes That Might Represent
Emergent Cases From a Highly
Pathogenic Influenza Virus of Pandemic
Potential
• Establish early-warning networks,
adapt international case definitions, and
implement standards for laboratory
diagnostics of human and animal
samples.
• Strengthen early-warning systems
for reporting human cases of infection
with influenza A (H5N1) by:
Æ Initiating or enhancing
Participation in the WHO Global
Outbreak Alert and Response Network
(GOARN) to report possible outbreaks of
highly pathogenic avian influenza in
humans and the WHO Global Influenza
Surveillance Network to share
specimens and viruses.
• Develop and establish village-based
public-sector alert-and-response
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
surveillance systems for human cases of
influenza. By providing health
education at the community level and to
providers and setting up a system for
reporting of suspect cases based on a
standard case definition.
• Develop a system that rapidly
notifies National Government
authorities of suspect avian influenza
cases and provides appropriate samples
for testing at the national level if the
capacity does not exist at a country’s
network site.
• Establish a system to monitor for
severe cases of respiratory illness for a
possible case or cluster of the H5N1
virus or other respiratory diseases that
pose a global threat.
• Develop protocols and tools to
investigate cases and clusters, including
the widespread dissemination of
specimen collection and transport
materials, to allow rapid diagnosis.
Note: The WHO-certified National
Influenza Center (NIC) within a country can
be one of the surveillance sites, and, as such,
conduct all the activities listed above under
components 2.3 and 2.4. However,
component 2.4 is often the responsibility of
units of Ministries of Health other than the
laboratory unit that serves as the National
Influenza Center, and Governments might
need to share resources across units and
establish protocols to fulfill the requirements
of components 2.3 and 2.4. If there are two
or more NICs within a country, each NIC
could participate as a site; however, NICs
within a single country should work together
and place emphasis on the addition of new
surveillance sites. In addition, the NIC(s)
should act as the focal point and authority
within the country on influenza surveillance,
and be the main point of communication
with the WHO Secretariat and WHO
Collaborating Centers for the rapid submittal
of virus isolates and information into the
global influenza surveillance system.
Pillar III. Response and Containment
3.1 Local Rapid-Response Teams
(RRT)
• Develop and adopt rapid-response
protocols for use in responding quickly
to credible reports of human-to-human
transmission that could indicate the
beginnings of an influenza pandemic.
Awardees may carry out this action in
conjunction with HHS, USAID, the
WHO Secretariat, and other donor
countries.
• Develop and train in-country rapidresponse teams to assess and report
quickly on possible outbreaks of avian
and human influenza at the village level
by accomplishing the following:
Æ Developing national and regional
rapid-response teams deployable within
24 hours; and,
Æ Working with GOARN to train
members of response teams and staff
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
57959
from Ministries of Health and
Agriculture. Training topics should
include outbreak investigations, cluster
investigations, case-control
investigations, and case-cohort
investigations.
3.2 Infection Control
• Develop local-language publichealth materials, in cooperation with
HHS that inform local health-care
workers and hospital administrators in
priority counties about infection-control
measures to control the spread of
pandemic influenza in health-care
facilities and in workplace health
facilities. The information should
include guidance about the appropriate
use of antiviral drugs and vaccines.
• Develop and/or field-test and
evaluate culturally and economically
appropriate standards for infectioncontrol practices and infrastructure for
international health-care settings.
• Develop economical and culturally
acceptable standardized preventive
practices for the routine delivery of
health-care that will be effective in
prevention of health-care-associated
influenza transmission during a
pandemic. (e.g., routine management
standards for febrile respiratory
illnesses).
• Develop and/or field-test and
evaluate culturally and economically
feasible community-based practices for
the prevention of infection in
community settings.
• Develop a costed national plan for
delivering basic infection-control
materials to and maintaining them in
District and Provincial hospitals, with
guidance for distribution and use in
preparation for and during the
anticipated disruptions caused by a
pandemic of influenza.
• Develop, in partnership with
international public-health agencies,
instructional material for print or
broadcast to target infection-control and
nursing personnel in local languages to
train them in appropriate cohorting,
cleaning, worker protection and the use
of protective equipment (e.g., gloves,
gowns, masks, etc.).
I. Funding Opportunity Description
Authority: Sections 301(a) and 307 of the
Public Health Service Act (42 U.S.C. 241(a)
and 42 U.S.C. 2421).
II. Award Information
The administrative and funding
instrument to be used for this program
will be the cooperative agreement in
which substantial OGHA/HHS scientific
and/or programmatic involvement is
anticipated during the performance of
the project. Under the cooperative
E:\FR\FM\02OCN1.SGM
02OCN1
57960
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
agreement, OGHA/HHS will support
and/or stimulate awardee activities by
working with them in a non-directive
partnership role. HHS staff is
substantially involved in the program
activities, above and beyond routine
monitoring. Through this cooperative
agreement, HHS will collaborate in an
advisory capacity with the award
recipient, especially during the
development and implementation of a
mutually agreed-upon work plan. HHS
will actively participate in periodic
progress reviews and a final evaluation
of the program.
Approximately $1,000,000.00 in fiscal
year (FY) 2006 funds is available to
support the agreement under the
Department of Defense, Emergency
Supplemental Appropriations to
Address Hurricanes in the Gulf of
Mexico, and Pandemic Influenza Act,
2006 which provides funds to combat a
potential influenza pandemic both
domestically and internationally.
The anticipated start date is October
27, 2006. There will only be one single
award made from this announcement.
The project period for this agreement is
for three (3) years with a budget period
of 12 months.
The award recipient must comply
with all HHS management requirements
for meeting participation and progress
and financial reporting for this
cooperative agreement. (Please see HHS
Activities and Program Evaluation
sections below.)
HHS/OS/OGHA activities for this
program are as follows:
rmajette on PROD1PC67 with NOTICES1
Pillar One
• Organize an orientation meeting
with the award recipient to brief them
on applicable U.S. Government
expectations, regulations, policies and
key management requirements, as well
as report formats and contents.
• Review and approve the process
used by the grantee to select key
personnel and/or post-award
subcontractors and/or sub grantees to be
involved in the activities performed
under this agreement.
• Review and approve the grantees’
annual work plan and detailed budget.
• Review and approve the grantees’
monitoring and evaluation plan,
including for compliance with the
performance management metrics and
systems developed for U.S. Government
and HHS assistance related to avian and
pandemic influenza.
• Meet or teleconference on a regular
basis, as necessary, with the grantee to
assess quarterly technical and financial
progress reports and modify plans as
necessary.
VerDate Aug<31>2005
18:50 Sep 29, 2006
Jkt 211001
• Meet on an annual basis with the
grantee to review annual progress report
for each U.S. Government fiscal year,
and to review annual work plans and
budgets for subsequent year.
• Provide technical assistance, as
mutually agreed upon, and revise
annually during validation of the first
and subsequent annual work plans. This
could include expert technical
assistance and targeted training
activities in specialized areas relevant to
influenza pandemic preparedness,
containment, and mitigation.
Pillar Two
• Provide technical assistance on
techniques and reagents for the
identification of influenza viruses.
Annually provide the WHO reagent kit,
produced and distributed by the WHO
Collaborating Center for Influenza at
HHS/OGHA;
• Providing epidemiological and
laboratory training;
• Providing technical consultation on
the development of in-country
influenza-surveillance networks;
• Providing confirmation of antigenic
analysis and more detailed
characterization information on the
influenza virus isolates submitted to
HHS/OGHA, with written reports back
to the National Influenza Center; and,
• Providing technical advice on the
conduct of local and regional
epidemiologic outbreak investigations.
Pillar Three
• Providing technical advice and
training in the development of local
rapid-response teams;
• Providing technical advice for the
development of policies and capabilities
for rapidly mobilizing materials from
stockpiles of pharmaceuticals and
commodities to the site of an outbreak;
and,
• Providing technical advice and
training in developing plans for
infection control.
III. Eligibility Information
1. Eligible Applicants
This is a single source, cooperative
agreement with the Ministry of Health
of the Great Socialist People’s Libyan
Arab Jamahiriya (Libya). On November
1, 2005, President George W. Bush
announced the U.S. National Strategy
for Pandemic Influenza, and the
following day Secretary Michael O.
Leavitt released the HHS Pandemic
Influenza Plan. One of the primary
objectives of both documents is to
leverage global partnerships to increase
preparedness and response capabilities
around the world ‘‘with the intent of
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
stopping, slowing or otherwise limiting
the spread of a pandemic to the United
States.’’1 Pillars Two and Three of the
National Strategy set out the clear goals
of ensuring the rapid reporting of
outbreaks and containing outbreaks
beyond the borders of the United States.
We rely upon our international
partnerships, with the United Nations
(UN); international organizations; and
private, non-profit organizations, to
amplify our efforts, and will engage
them on a multilateral and bilateral
basis. Our international effort to contain
and mitigate the effects of an outbreak
of pandemic influenza is a central
component of our overall strategy. In
many ways, the character and quality of
the U.S. response and that of our
international partners could play a
determining role in the severity of a
pandemic.
The International Partnership on
Avian and Pandemic Influenza,
launched by President Bush at the UN
General Assembly in September 2005,
stands in support of multinational
organizations and national
Governments. Members of the
Partnership have agreed that the
following ten principles will guide their
efforts:
1. International cooperation to protect
the lives and health of our people;
2. Timely and sustained, high-level,
global, political leadership to combat
avian and pandemic influenza;
3. Transparency in reporting of
influenza cases in humans and in
animals caused by viruses trains that
have pandemic potential, to increase
understanding and preparedness, and
especially to ensure rapid and timely
response to potential outbreaks;
4. Immediate sharing of
epidemiological data and samples with
the World Health Organization (WHO)
and the international community to
detect and characterize the nature and
evolution of any outbreaks as quickly as
possible, by using, where appropriate,
existing networks and mechanisms;
5. Rapid reaction to address the first
signs of accelerated transmission of
H5N1 and other highly pathogenic
influenza strains, so appropriate
international and national resources can
be brought to bear;
6. Prevent and contain an incipient
epidemic through capacity- building
and in-country collaboration with
international partners;
7. Work in a manner complementary
to and supportive of expanded
cooperation with and appropriate
support of key multilateral
organizations (including the WHO, Food
1 National
E:\FR\FM\02OCN1.SGM
Strategy for Pandemic Influenza, p. 2.
02OCN1
rmajette on PROD1PC67 with NOTICES1
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
and Agriculture Organization, and the
World Organization for Animal Health);
8. Timely coordination of bilateral
and multilateral resource allocations;
dedication of domestic resources
(human and financial); improvements in
public awareness; and development of
economic and trade contingency plans;
9. Increased coordination and
harmonization of preparedness,
prevention, response and containment
activities among nations,
complementing domestics and regional
preparedness initiatives, and
encouraging where appropriate the
development of strategic regional
initiatives; and,
10. Actions based on the best
available science.
Through the Partnership and other
bilateral and multilateral initiatives, we
will promote these principles and
support the development of an
international capacity to prepare for,
detect, and respond to an influenza
pandemic. Based on an overall public
health analysis for pandemic flu, Libya
requires assistance in detection,
surveillance and other areas to manage
and identify Avian Influenza.
Avian Influenza is a significant
burden on neighboring countries of
Libya. Egypt, for example, has
consistently identified the H5N1 virus
in poultry and humans resulting in
human fatalities and the near
decimation of its poultry industry.
Other countries proximate to Libya
which have reported human cases of
H5N1 include Turkey, Iraq, and
Azerbaijan. Sharing the same bird flyways and trading goods daily with many
of its neighboring countries already
affected by H5N1, Libya is at heightened
risk. For these reasons, eligibility for
this cooperative agreement is limited to
the country of Libya.
Twenty-two years of sanctions has
isolated Libya from the rest of the world
and exacerbated the seriousness of the
situation within Libya. The sanctions
have prevented Libya from experiencing
the benefits of medical training in stateof-the art practice and scientific
collaborations leaving Libya vulnerable
to an influenza pandemic.
Libya recently appointed its first
Minister of Health and is in the early
stages of developing a Ministry of
Health. Previously, under the General
People’s Committee for Health and
Environment of the Great Socialist
People’s Libyan Arab Jamahiriya, public
health services did not in exist. With the
control and governance of public health
services now delegated to Libya’s
Ministry of Health, the Ministry of
Health assumes responsibility for
developing and building the capacity of
VerDate Aug<31>2005
18:50 Sep 29, 2006
Jkt 211001
the public health care system.
Therefore, in accordance with the
guidance presented here, and the
demand to seek Ministers of Health of
countries affected, the only eligible
source for any efforts in building the
capacity of the public health care
system in the country of Libya is the
Minister of Health.
2. Cost-Sharing or Matching
Although cost-sharing, matching
funds, and cost participation are not a
requirement of this agreement,
preference may go to organizations that
can leverage additional funds to
contribute to program goals. If
applicants receive funding from other
sources to underwrite the same or
similar activities, or anticipate receiving
such funding in the next 12 months,
they must detail how the disparate
streams of financing complement each
other.
3. Other - (If Applicable)
If an applicant requests a funding
amount greater than the ceiling of the
award range, HHS will consider the
application non-responsive, and it will
not enter into the review process. HHS
will notify the applicant that the
application did not meet the submission
requirements.
IV. Application and Submission
Information
1. Address To Request Application
Package:
This Cooperative Agreement project
uses the Application Form HHS Office
of Public Health and Science (OPHS)
OPHS–1, Revised 8/2004, enclosed in
the application packet. Many different
programs funded through the HHS
Public Health Service (PHS) use this
generic form. Some parts of it are not
required; applicants must fill out other
sections in a fashion specific to the
program. Instructions for filling out
OPHS–1, Revised 8/2004 will be
included in the application packet.
These forms are also available from the
following sites by downloading from
https://egrants.osophs.dhhs.gov and
clicking on Grant Announcements, or
https://www.grants.gov/; or by writing to
Ms. Karen Campbell, Director, Office of
Grants Management, Office of Public
Health and Science, U.S. Department of
Health and Human Services, Tower
Building, 1101 Wootton Parkway, Suite
550, Rockville, MD 20852; or by
contacting the HHS/OPHS Office of
Grants Management, at 1–(240) 453–
8822. Please specify the HHS program(s)
for which you are requesting an
application kit.
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
57961
Application kits may be
requested from, and applications
submitted to Karen Campbell, Director,
Office of Grants Management, Office of
Public Health and Science (OPHS),
Department of Health and Human
Services, 1101 Wootton Parkway, Suite
550, Rockville, MD 20852.
ADDRESSES:
2. Content and Form of Application
Submission
Application Materials
A separate budget page is required for
the budget year requested. Applicants
must submit with the proposal a lineitem budget (SF 424A) with coinciding
justification to support each of the
budget years. These forms will represent
the full project period of Federal
assistance requested. HHS will not
favorably consider proposals submitted
without a budget and justification for
each budget year requested in the
application. Specific instructions for
submitting a detailed budget for this
application appear in the application
packet. If additional information and/or
clarification are necessary, please
contact the HHS/OPHS Office of Grants
Management identified in Section VII of
this announcement.
A Project Abstract submitted on 3.5
inch floppy disk must accompany all
applications. The abstract must be
typed, single-spaced, and not exceed
two pages. Reviewers and staff will refer
frequently to the information contained
in the abstract, and therefore it should
contain substantive information about
the proposed projects in summary form.
A list of suggested keywords and a
format sheet for your use in preparing
the abstract will be included in the
application packet.
A Project Narrative must accompany
all grant applications. In addition to the
instructions provided in OPHS–1 (Rev
8/2004) for project narrative, the
specific guidelines for the project
narrative appear in the program
guidelines. Format requirements are the
same as for the Project Abstract Section;
margins should be one inch at the top
and one inch at the bottom and both
sides; and typeset must be no smaller
than 12 cpi, and not reduced.
Applicants should type biographical
sketches either on the appropriate form
or on plain paper, and should not
exceed two pages, with publications
listed limited only to those that are
directly relevant to this project.
Application Format Requirements
If applying on paper, the entire
application may not exceed 80 pages in
length, including theabstract, project
and budget narratives, face page,
E:\FR\FM\02OCN1.SGM
02OCN1
57962
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
attachments, any appendices and letters
of commitment and support. Applicants
must number pages consecutively.
HHS/OGHA will deem as noncompliant applications submitted
electronically that exceed 80 pages
when printed and will return all noncompliant applications to the applicant
without further consideration.
(a) Number of Copies: Please submit
one (1) original and two (2) unbound
copies of the application. Please do not
bind or staple the application.
Application must be single- sided.
(b) Font: Please use an easily readable
serif typeface, such as Times Roman,
Courier, or CG Times. Applicants must
submit the text and table portions of the
application in not less than 12-point
and 1.0 line spacing. HHS/OGHA might
return applications that do not adhere to
12-point font requirements.
(c) Paper Size and Margins: For
scanning purposes, please submit the
application on 81⁄2″ x 11″ white paper.
Margins must be at least one (1) inch at
the top, bottom, left and right of the
paper. Please left-align text.
(d) Numbering: Please number the
pages of the application sequentially
from page one (face page) to the end of
the application, including charts,
figures, tables, and appendices.
(e) Names: Please include the name of
the applicant on each page.
(f) Section Headings: Please put all
section headings flush left in bold type.
rmajette on PROD1PC67 with NOTICES1
Application Format
An application for funding must
consist of the following documents in
the following order:
i. Application Face Page: Public
Health Service (PHS) Application Form
OPHS–1, provided with the application
package. Prepare this page according to
instructions provided in the form itself.
DUNS Number
An applicant organization is required
to have a Data Universal Numbering
System (DUNS) number in order to
apply for a grant from the Federal
Government. The DUNS number is a
unique nine-character identification
number provided by the commercial
company, Dun and Bradstreet. There is
no charge to obtain a DUNS number.
Information about obtaining a DUNS
number can be found at https://
www.dnb.com/product/eupdate/
requestOptions.html or call 1–866–705–
5711. Please include the DUNS number
next to the OMB Approval Number on
the application face page. An
application will not be reviewed
without a DUNS number.
Additionally, the applicant
organization will be required to register
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
with the Federal Government’s Central
Contractor Registry (CCR) in order to do
electronic business with the Federal
Government. Information about
registering with the CCR can be found
at https://www.hrsa.gov/grants/ccr.htm.
Finally, an applicant applying
electronically through Grants.gov is
required to register with the Credential
Provider for Grants.gov. Information
about this requirement is available at
https://www.grants.gov/
CredentialProvider
An applicant applying electronically
through the OPHS E-Grants System is
required to register with the provider.
Information about this requirement is
available at https://
egrants.osophs.dhhs.gov.
ii. Table of Contents: Provide a Table
of Contents for the remainder of the
application (including appendices),
with page numbers.
iii. Application Checklist: Application
Form OPHS–1, provided with the
application package.
iv. Budget: Application Form OPHS–
1, provided with the application
package.
v. Budget Justification: The amount of
financial support (direct costs) that an
applicant is requesting from the Federal
granting agency for the first year is to be
entered on the Face Sheet of
Application Form PHS 5161–1, Line
15a. The application should include
funds for electronic mail capability
unless access by Internet is already
available. The amount of financial
support (direct costs) entered on the SF
424 is the amount an applicant is
requesting from the Federal granting
agency for the project year.
Personnel Costs: Personnel costs
should be explained by listing each staff
member who will be supported from
funds, name (if possible), position title,
percent full time equivalency, annual
salary, and the exact amount requested.
Fringe Benefits: List the components
that comprise the fringe benefit rate, for
example health insurance, taxes,
unemployment insurance, life
insurance, retirement plan, tuition
reimbursement. The fringe benefits
should be directly proportional to that
portion of personnel costs that are
allocated for the project.
Travel: List travel costs according to
local and long distance travel. For local
travel, the mileage rate, number of
miles, reason for travel and staff
member/consumers completing the
travel should be outlined. The budget
should also reflect the travel expenses
associated with participating in
meetings and other proposed trainings
or workshops.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Equipment: List equipment costs and
provide justification for the need of the
equipment to carry out the programs
goals. Extensive justification and a
detailed status of current equipment
must be provided when requesting
funds for the purchase of computers and
furniture items.
Supplies: List the items that the
project will use. In this category,
separate office supplies from medical
and educational purchases. Office
supplies could include paper, pencils,
and the like; medical supplies are
syringes, blood tubes, plastic gloves,
etc., and educational supplies may be
pamphlets and educational videotapes.
Remember, they must be listed
separately.
Subcontracts: To the extent possible,
all subcontract budgets and
justifications should be standardized,
and contract budgets should be
presented by using the same object class
categories contained in the Standard
Form 424A. Provide a clear explanation
as to the purpose of each contract, how
the costs were estimated, and the
specific contract deliverables.
Other: Put all costs that do not fit into
any other category into this category and
provide an explanation of each cost in
this category. In some cases, grantee
rent, utilities and insurance fall under
this category if they are not included in
an approved indirect cost rate.)
vi.Staffing Plan and Personnel
Requirements: An applicant must
present a staffing plan and provide a
justification for the plan that includes
education and experience qualifications
and rationale for the amount of time
being requested for each staff position.
Position descriptions that include the
roles, responsibilities, and qualifications
of proposed project staff must be
included in Appendix B. Copies of
biographical sketches for any key
employed personnel that will be
assigned to work on the proposed
project must be included in Appendix
C.
vii. Project Abstract: Provide a
summary of the application. Because the
abstract is often distributed to provide
information to the public and Congress,
please prepare this so that it is clear,
accurate, concise, and without reference
to other parts of the application. It must
include a brief description of the
proposed grant project including the
needs to be addressed, the proposed
services, and the population group(s) to
be served.
Please place the following at the top
of the abstract:
• Project Title;
• Applicant Name;
• Address;
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
• Contact Phone Numbers (Voice,
Fax);
• E-Mail Address; and,
• Web site Address, if applicable.
The project abstract must be singlespaced and limited to two pages in
length.
viii. Program Narrative: This section
provides a comprehensive framework
and description of all aspects of the
proposed program. It should be
succinct, self-explanatory and well
organized so that reviewers can
understand the proposed project.
Use the following section headers for
the Narrative:
Introduction
This section should briefly describe
the purpose of the proposed project.
Work Plan
Describe the activities or steps that
will be used to achieve each of the
activities proposed in the methodology
section. Use a time line that includes
each activity and identifies responsible
staff.
Resolution of Challenges
Discuss challenges that are likely to
be encountered in designing and
implementing the activities described in
the Work Plan, and approaches that will
be used to resolve such challenges.
Evaluation and Technical Support
Capacity
Describe current experience, skills,
and knowledge, including individuals
on staff, materials published, and
previous work of a similar nature.
rmajette on PROD1PC67 with NOTICES1
Organizational Information
Provide information on the applicant
agency’s current mission and structure,
scope of current activities, and an
organizational chart, and describe how
these all contribute to the ability of the
organization to conduct the program
requirements and meet program
expectations.
ix. Appendices: Please provide the
following items to complete the content
of the application. Please note that these
are supplementary in nature, and are
not intended to be a continuation of the
project narrative. Be sure each appendix
is clearly labeled.
1. Appendix A: Tables, Charts, etc.
To give further details about the
proposal.
2. Appendix B: Job Descriptions for
Key Personnel.
Keep each to one page in length as
much as is possible. Item 6 in the
Program Narrative section of the PHS
5161–1 Form provides some guidance
on items to include in a job description.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
3. Appendix C: Biographical Sketches
of Key Personnel.
Include biographical sketches for
persons occupying the key positions
described in Appendix B, not to exceed
two pages in length. In the event that a
biographical sketch is included for an
identified individual who is not yet
hired, please include a letter of
commitment from that person with the
biographical sketch.
4. Appendix D: Letters of Agreement
and/or Description(s) of Proposed/
Existing Contracts (project specific).
Provide any documents that describe
working relationships between the
applicant agency and other agencies and
programs cited in the proposal.
Documents that confirm actual or
pending contractual agreements should
clearly describe the roles of the
subcontractors and any deliverable.
Letters of agreements must be dated.
5. Appendix E: Project Organizational
Chart.
Provide a one-page figure that depicts
the organizational structure of the
project, including subcontractors and
other significant collaborators.
6. Appendix F: Other Relevant
Documents.
Include here any other documents
that are relevant to the application,
including letters of supports. Letters of
support must be dated.
3. Submission Dates & Times
The Office of Public Health and
Science (OPHS) provides multiple
mechanisms for the submission of
applications, as described in the
following sections. Applicants will
receive notification via mail from the
OPHS Office of Grants Management
confirming the receipt of applications
submitted using any of these
mechanisms. Applications submitted to
the OPHS Office of Grants Management
after the deadlines described below will
not be accepted for review. Applications
which do not conform to the
requirements of the grant announcement
will not be accepted for review and will
be returned to the applicant.
Applications may only be submitted
electronically via the electronic
submission mechanisms specified
below. Any applications submitted via
any other means of electronic
communication, including facsimile or
electronic mail, will not be accepted for
review. While applications are accepted
in hard copy, the use of the electronic
application submission capabilities
provided by the OPHS eGrants system
or the Grants.gov Web site Portal is
encouraged.
Electronic grant application
submissions must be submitted no later
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
57963
than 5:00 p.m. Eastern Time on the
deadline date specified in the DATES
section of the announcement using one
of the electronic submission
mechanisms specified below. All
required hard-copy original signatures
and mail-in items must be received by
the OPHS Office of Grants Management
no later that 5 p.m. Eastern Time on the
next business day after the deadline
date specified in the DATES section of
the announcement.
Applications will not be considered
valid until all electronic application
components, hard copy original
signatures, and mail-in items are
received by the OPHS Office of Grants
Management according to the deadlines
specified above. Application
submissions that do not adhere to the
due date requirements will be
considered late and will be deemed
ineligible.
Applicants are encouraged to initiate
electronic applications early in the
application development process, and to
submit early on the due date or before.
This will aid in addressing any
problems with submissions prior to the
application deadline.
Electronic Submissions Via the
Grants.gov Web Site Portal
The Grants.gov Web site Portal
provides organizations with the ability
to submit applications for OPHS grant
opportunities. Organizations must
successfully complete the necessary
registration processes in order to submit
an application. Information about this
system is available on the Grants.gov
Web site, https://www.grants.gov.
In addition to electronically
submitted materials, applicants may be
required to submit hard copy signatures
for certain Program related forms, or
original materials as required by the
announcement. It is imperative that the
applicant review both the grant
announcement, as well as the
application guidance provided within
the Grants.gov application package, to
determine such requirements. Any
required hard copy materials, or
documents that require a signature,
must be submitted separately via mail to
the OPHS Office of Grants Management,
and, if required, must contain the
original signature of an individual
authorized to act for the applicant
agency and the obligations imposed by
the terms and conditions of the grant
award.
Electronic applications submitted via
the Grants.gov Web site Portal must
contain all completed online forms
required by the application kit, the
Program Narrative, Budget Narrative
and any appendices or exhibits. All
E:\FR\FM\02OCN1.SGM
02OCN1
57964
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
required mail-in items must received by
the due date requirements specified
above. Mail-In items may only include
publications, resumes, or organizational
documentation.
Upon completion of a successful
electronic application submission via
the Grants.gov Web site Portal, the
applicant will be provided with a
confirmation page from Grants.gov
indicating the date and time (eastern
time) of the electronic application
submission, as well as the Grants.gov
Receipt Number. It is critical that the
applicant print and retain this
confirmation for their records, as well as
a copy of the entire application package.
All applications submitted via the
Grants.gov Web site Portal will be
validated by Grants.gov. Any
applications deemed ≥Invalid≥ by the
Grants.gov Web site Portal will not be
transferred to the OPHS eGrants system,
and OPHS has no responsibility for any
application that is not validated and
transferred to OPHS from the Grants.gov
Web site Portal. Grants.gov will notify
the applicant regarding the application
validation status. Once the application
is successfully validated by the
Grants.gov Web site Portal, applicants
should immediately mail all required
hard-copy materials to the OPHS Office
of Grants Management to be received by
the deadlines specified above. It is
critical that the applicant clearly
identify the Organization name and
Grants.gov Application Receipt Number
on all hard-copy materials.
Once the application is validated by
Grants.gov, it will be electronically
transferred to the OPHS eGrants system
for processing. Upon receipt of both the
electronic application from the
Grants.gov Website Portal, and the
required hard-copy mail-in items,
applicants will receive notification via
mail from the OPHS Office of Grants
Management confirming the receipt of
the application submitted using the
Grants.gov Web site Portal.
Applicants should contact Grants.gov
regarding any questions or concerns
regarding the electronic application
process conducted through the
Grants.gov Web site Portal.
rmajette on PROD1PC67 with NOTICES1
Electronic Submissions via the OPHS
eGrants System
The OPHS electronic grants
management system, eGrants, provides
for applications to be submitted
electronically. Information about this
system is available on the OPHS eGrants
Web site, https://
egrants.osophs.dhhs.gov, or may be
requested from the OPHS Office of
Grants Management at (240) 453–8822.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
When submitting applications via the
OPHS eGrants system, applicants are
required to submit a hard copy of the
application face page (Standard Form
424) with the original signature of an
individual authorized to act for the
applicant agency and assume the
obligations imposed by the terms and
conditions of the grant award. If
required, applicants will also need to
submit a hard copy of the Standard
Form LLL and/or certain Program
related forms (e.g., Program
Certifications) with the original
signature of an individual authorized to
act for the applicant agency.
Electronic applications submitted via
the OPHS eGrants system must contain
all completedonline forms required by
the application kit, the Program
Narrative, Budget Narrative and any
appendices or exhibits. The applicant
may identify specific mail-in items to be
sent to the Office of Grants Management
separate from the electronic submission;
however these mail-in items must be
entered on the eGrants Application
Checklist at the time of electronic
submission, and must be received by the
due date requirements specified above.
Mail-in items may only include
publications, resumes, or organizational
documentation.
Upon completion of a successful
electronic application submission, the
OPHS eGrants system will provide the
applicant with a confirmation page
indicating the date and time (eastern
time) of the electronic application
submission. This confirmation page will
also provide a listing of all items that
constitute the final application
submission including all electronic
application components, required
hardcopy original signatures, and mailin items, as well as the mailing address
of the OPHS Office of Grants
Management where all required hard
copy materials must be submitted. As
items are received by the OPHS Office
of Grants Management, the electronic
application status will be updated to
reflect the receipt of mail-in items. It is
recommended that the applicant
monitor the status of their application in
the OPHS eGrants system to ensure that
all signatures and mail-in items are
received.
Mailed or Hand-Delivered Hard Copy
Applications
Applicants who submit applications
in hard copy (via mail or handdelivered) are required to submit an
original and two copies of the
application. The original application
must be signed by an individual
authorized to act for the applicant
agency or organization and to assume
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
for the organization the obligations
imposed by the terms and conditions of
the grant award.
Mailed or hand-delivered applications
will be considered as meeting the
deadline if they are received by the
OPHS Office of Grant Management on or
before 5 p.m. eastern time on the
deadline date specified in the DATES
section of the announcement. The
application deadline date requirement
specified in this announcement
supersedes the instructions in the
OPHS–1. Applications that do not meet
the deadline will be returned to the
applicant unread. Applicants should
submit their applications to the
following address: Director, Office of
Grants Management, Office of Public
Health and Science, U.S. Department of
Health and Human Services, 1101
Wootten Parkway, Suite 550, Rockville,
MD 20852.
4. Intergovernmental Review
This program is not subject to the
review requirements of Executive Order
12372, Intergovernmental Review of
Federal Programs.
5. Funding Restrictions
Allowability, allocability,
reasonableness, and necessity of direct
costs that may be charged are outlined
in the following documents: OMB–21
(Institutes of Higher Education); OMB
Circular A–122 (Nonprofit
Organizations) and 45 CFR Part 74,
Appendix E (Hospitals). Copies of these
circulars are available on the Internet at
the following address: https://
www.whitehouse.gov/omb. No preaward costs are allowed.
6. Other Submission Requirements
N/A.
V. Application Review Information
1. Criteria
The application will be screened by
OGHA staff for completeness and for
responsiveness to the program guidance.
The applicant should pay strict
attention addressing these criteria, as
they are the basis upon which
applications will be judged. An
application judged to be non-responsive
or incomplete will be returned to the
applicant without review.
An application that is complete and
responsive to the guidance will be
evaluated for scientific and technical
merit by an appropriate peer review
group specifically convened for this
solicitation and in accordance with HHS
policies and procedures. As part of the
initial merit review, all applications will
receive a written critique. All
applications recommended for approval
E:\FR\FM\02OCN1.SGM
02OCN1
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
will be discussed fully by the ad hoc
peer review group and assigned a
priority score for funding. Eligible
applications will be assessed according
the following criteria:
(1) Technical Approach (40 Points)
• The applicant’s presentation of a
sound and practical technical approach
for executing the requirements with
adequate explanation, substantiation
and justification for methods for
handling the projected needs of the
partner institution.
• The successful applicant must
demonstrate a clear understanding of
the scope and objectives of the
cooperative agreement, recognition of
potential difficulties that could arise in
performing the work required,
presentation of adequate solutions, and
understanding of the close coordination
necessary between the HHS/OGHA, the
International Partnership on Avian and
Pandemic Influenza, United Nations
agencies, and the WHO Secretariat.
• Applicants must submit a strategic
plan that outlines the schedule of
activities and expected products of the
Group’s work with benchmarks at
months six and 12. The strategic plan
should specifically address the expected
progress of the Quality of Care program.
rmajette on PROD1PC67 with NOTICES1
(2) Personnel Qualifications and
Experience (20 Points)
• Project Leadership— For the
technical and administrative leadership
of the project requirements, successful
applicants must demonstrate
documented training, expertise, relevant
experiences, leadership/management
skills, and the availability of a suitable
overall project manager and
surrounding management structure to
successfully plan and manage the
project. The successful applicant will
provide documented history of
leadership in the establishment and
management of training programs that
involve training of health-care
professionals in countries other than the
United States. Expertise in maternal and
child health care, including
documented training, expertise, relevant
experience, leadership skills, and
medical expertise specific to maternal
and child health. Documented
managerial ability to achieve delivery or
performance requirements as
demonstrated by the proposed use of
management and other personnel
resources and to manage successfully
the project, including subcontractor
and/or consultant efforts, if applicable,
as evidence by the management plan
and demonstrated by previous relevant
experience.
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
• Partner Institutions and other
Personnel—Applicants should provide
documented evidence of availability,
training, qualifications, expertise,
relevant experience, education and
competence of the scientific, clinical,
analytical, technical and administrative
staff and any other proposed personnel
(including partner institutions,
subcontractors and consultants), to
perform the requirements of the work
activities as evidenced by resumes,
endorsements and explanations of
previous efforts.
• Staffing Plan—Applicants should
submit a staffing plan for the conduct of
the project, including the
appropriateness of the time commitment
of all staff and partner institutions, the
clarity and appropriateness of assigned
roles, and lines of authority. Applicants
should also provide an organizational
chart for each partner institution named
in the application showing relationships
among the key personnel.
• Administrative and Organizational
Framework—Adequacy of the
administrative and organizational
framework, with lines of authority and
responsibility clearly demonstrated, and
adequacy of the project plan, with
proposed time schedule for achieving
objectives and maintaining quality
control over the implementation and
operation of the project. Adequacy of
back-up staffing and the evidence that
they will be able to function as a team.
The framework should identify the
institution that will assume legal and
financial responsibility and
accountability for the use and
disposition of funds awarded on the
basis of this RFA.
(3) Experience and Capabilities of the
Organization (30 Points)
• Applicant should submit
documented relevant experience of the
organization in managing projects of
similar complexity and scope of the
activities.
• Clarity and appropriateness of lines
of communication and authority for
coordination and management of the
project. Adequacy and feasibility of
plans to ensure successful coordination
of a multiple-partner collaboration.
• Documented experience recruiting
qualified medical personnel for projects
of similar complexity and scope of
activities.
(4) Facilities and Resources (10 Points)
• Documented availability and
adequacy of facilities, equipment and
resources necessary to carry out the
activities specified under Program
Requirements.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
57965
VI. Award Administration Information
1. Award Notices
HHS/OGHA does not release
information about individual
applications during the review process
until we have made final funding
decisions. When HHS/OGHA has made
these decisions, we will notify
applicants by letter regarding the
outcome of their applications. The
official document to notify an applicant
HHS/OGHA has approved and funded
an application is the Notice of Award,
which specifies to the recipient the
amount of money awarded, the purpose
of the agreement, the terms and
conditions of the agreement, and the
amount of funding, if any, the recipient
will contribute to the project costs.
2. Administrative and National Policy
Requirements
The regulations set out at 45 CFR
parts 74 and 92 are the U.S. Department
of Health and Human Services (HHS)
rules and requirements that govern the
administration of grants. Part 74 is
applicable to all recipients except those
covered by part 92, which governs
awards to State and Local governments.
Applicants funded under this
announcement must be aware of and
comply with these regulations. The CFR
volume that includes parts 74 and 92
are available from the following Internet
address: https://www.access.gpo.gov/
nara/cfr/waisidx_03/45cfrv1_03.html.
3. Reporting
The projects is required to have an
evaluation plan, consistent with the
scope of the proposed project and
funding level that conforms to the
project’s stated goals and objectives. The
evaluation plan should include both a
process evaluation to track the
implementation of project activities and
an outcome evaluation to measure
changes in knowledge and skills that
can be attributed to the project. Project
funds may be used to support
evaluation activities.
In addition to conducting their own
evaluation of projects, the successful
applicant must be prepared to
participate in an external evaluation, to
be supported by OGHA/HHS and
conducted by an independent entity, to
assess efficiency and effectiveness for
the project funded under this
announcement.
Within 30 days following the end of
each of quarter, submit a performance
report no more than ten pages in length
must be submitted to OGHA/HHS. A
sample quarterly performance report
will be provided at the time of
notification of award. At a minimum,
E:\FR\FM\02OCN1.SGM
02OCN1
rmajette on PROD1PC67 with NOTICES1
57966
Federal Register / Vol. 71, No. 190 / Monday, October 2, 2006 / Notices
quarterly performance reports should
include:
• Concise summary of the most
significant achievements and problems
encountered during the reporting
period, e.g. number of training courses
held and number of trainees.
• A comparison of work progress
with objectives established for the
quarter using the grantee’s
implementation schedule, and where
such objectives were not met, a
statement of why they were not met.
• Specific action(s) that the grantee
would like the OGHA/HHS to undertake
to alleviate a problem.
• Other pertinent information that
will permit monitoring and overview of
project operations.
• A quarterly financial report
describing the current financial status of
the funds used under this award. The
awardee and OGHA will agree at the
time of award for the format of this
portion of the report.
Within 90 days following the end of
the project period a final report
containing information and data of
interest to the Department of Health and
Human Services, Congress, and other
countries must be submitted to OGHA/
HHS. The specifics as to the format and
content of the final report and the
summary will be sent to successful
applicants. At minimum, the report
should contain:
• A summary of the major activities
supported under the agreement and the
major accomplishments resulting from
activities to improve mortality in
partner country.
• An analysis of the project based on
the problem(s) described in the
application and needs assessments,
performed prior to or during the project
period, including a description of the
specific objectives stated in the grant
application and the accomplishments
and failures resulting from activities
during the grant period.
Quarterly performance reports and the
final report may be submitted to: Mr.
DeWayne Wynn, Grants Management
Specialist, Office of Grants
Management, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 550, Rockville, MD
20852, phone (240) 453–8822.
A Financial Status Report (FSR) SF–
269 is due 90 days after the close of each
12-month budget period and submitted
to OPHS–Office of Grants Management.
VII. Agency Contacts
For assistance on administrative and
budgetary requirements, please contact:
Mr. DeWayne Wynn, Grants
Management Specialist, Office of Grants
VerDate Aug<31>2005
15:07 Sep 29, 2006
Jkt 211001
Management, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Suite 550, Rockville, MD
20852, phone (240) 453–8822.
For assistance with questions
regarding program requirements, please
contact the following: David Smith,
PhD, Office of Global Health Affairs,
U.S. Department of Health and Human
Services, 5600 Fishers Lane, Suite 18–
101, Rockville, MD 20857; Phone
Number: 1–301–443–1774.
VIII. Tips for Writing a Strong
Application
Include DUNS Number. You must
include a DUNS Number to have your
application reviewed. HHS/OGHA will
not review applications without a DUNS
number. To obtain a DUNS number, go
to https://www.dunandbradstreet.com or
call 1–866–705–5711. Please include the
DUNS number next to the OMB
Approval Number on the application
face page.
Keep your audience in mind.
Reviewers will use only the information
contained in the application to assess
the application. Be sure the application
and responses to the program
requirements and expectations are
complete and clearly written. Do not
assume reviewers are familiar with the
applicant organization. Keep the review
criteria in mind when writing the
application.
Start preparing the application early.
Allow plenty of time to gather required
information from various sources.
Follow the instructions in this
guidance carefully. Place all information
in the order requested in the guidance.
If the applicant does not place
information in the requested order, the
application might receive a lower score.
Be brief, concise, and clear. Make
your points understandable. Provide
accurate and honest information,
including candid accounts of problems
and realistic plans to address them. If
any required information or data is
omitted, explain why. Make sure the
information provided in each table,
chart, attachment, etc., is consistent
with the proposal narrative and
information in other tables.
Be organized and logical. Many
applications fail to receive a high score
because the reviewers cannot follow the
thought process of the applicant or
because parts of the application do not
fit together.
Be careful in the use of appendices.
Do not use the appendices for
information that is required in the body
of the application. Be sure to crossreference all tables and attachments
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
located in the appendices to the
appropriate text in the application.
Carefully proofread the application.
Misspellings and grammatical errors
will impede reviewers in understanding
the application. Be sure pages are
numbered (including appendices), and
follow page limits. Limit the use of
abbreviations and acronyms, and define
each one at its first use and periodically
throughout the application.
Dated: September 26, 2006.
Sandra R. Manning,
Deputy Director for Operations, Office of
Global Health Affairs, U.S. Department of
Health and Human Services.
[FR Doc. E6–16181 Filed 9–29–06; 8:45 am]
BILLING CODE 4150–38–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Presidential Advisory
Council on HIV/AIDS
Office of Public Health and
Science, Office of the Secretary,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
SUMMARY: As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (DHHS) is hereby giving notice
that the Presidential Advisory Council
on HIV/AIDS (PACHA) will hold a
meeting. This meeting is open to the
public. A description of the Council’s
functions is included with this notice.
DATES: October 16, 2006, 8 a.m. to 5
p.m., and October 17, 2006, 8 a.m. to 4
p.m.
ADDRESSES: Howard University, Armour
J. Blackburn University Center, 2397
Sixth Street, NW., Washington, DC
20059.
FOR FURTHER INFORMATION CONTACT:
Dana Ceasar, Program Assistant,
Presidential Advisory Council on HIV/
AIDS, Department of Health and Human
Services, Hubert H. Humphrey Building,
200 Independence Avenue, SW., Room
733E, Washington, DC 20201; (202)
690–2470 or visit the Council’s Web site
at https://www.pacha.gov.
SUPPLEMENTARY INFORMATION: PACHA
was established by Executive Order
12963, dated June 14, 1995, as amended
by Executive Order 13009, dated June
14, 1996. The Council was established
to provide advice, information, and
recommendations to the Secretary
regarding programs and policies
intended to (a) promote effective
prevention of HIV disease, (b) advance
research on HIV and AIDS, and (c)
E:\FR\FM\02OCN1.SGM
02OCN1
Agencies
[Federal Register Volume 71, Number 190 (Monday, October 2, 2006)]
[Notices]
[Pages 57955-57966]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-16181]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Surveillance and Response to Highly Pathogenic Avian and Pandemic
Influenza in the Libyan Arab Jamahiriya
AGENCY: Office of Global Health Affairs, Office of the Secretary, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
Announcement Type: Single Eligibility--FY 2006 Initial
Announcement.
Funding Opportunity Number: OGHA 06-025.
GSA Catalog of Federal Domestic Assistance: 93. 283.
DATES: October 2, 2006: Application Availability.
October 10, 2006: Optional Letter of Intent due by 5 p.m. ET.
October 17, 2006: Application due by 5 p.m. ET.
October 27, 2006: Award date.
SUMMARY: An influenza pandemic has greater potential than any other
naturally occurring infectious disease to cause large and rapid global
and domestic increases in death and serious illness. Preparedness is
the key to substantially reducing the health, social, and economic
impacts of an influenza pandemic and other public-health emergencies.
On November 1, 2005, President George W. Bush announced the U.S.
National Strategy for Pandemic Influenza and the following day,
Secretary Michael O. Leavitt released the HHS Pandemic Influenza Plan.
One of the primary objectives of both documents is to leverage global
partnerships to increase preparedness and response capabilities around
the world with the intent of stopping, slowing, or otherwise limiting
the spread of a pandemic to the United States.\1\ Pillars Two and Three
of the National Strategy set out the clear goals of ensuring the rapid
reporting of outbreaks and containing outbreaks beyond the borders of
the United States, by taking the following actions:
---------------------------------------------------------------------------
\1\ National Stragegy for Pandemic Influenza, p. 2.
---------------------------------------------------------------------------
Working through the International Partnership on Avian and
Pandemic Influenza, as well as through other political and diplomatic
channels, such as the United Nations and the Asia-Pacific Economic
Cooperation Forum, to ensure transparency, scientific cooperation, and
the rapid reporting of highly pathogenic avian and human influenza
cases;
Supporting the development of the proper scientific and
epidemiological expertise in affected regions to ensure the early
recognition of changes in the pattern of highly pathogenic avian or
human influenza outbreaks;
Supporting the development and maintenance of sufficient
host-country laboratory capacities and diagnostic reagents in affected
regions, to provide rapid confirmation of cases of influenza in animals
and humans;
Working through the International Partnership to develop a
coalition of strong partners to coordinate containment efforts, that
is, actions to limit the spread of an influenza with pandemic potential
beyond where it is first located; and,
Providing guidance to all levels of Government in affected
nations on the range of options for risk-communication, infection-
control, and containment.
We rely upon our international partnerships, with the United
Nations (UN); international organizations; and private and non-profit
organizations, to amplify our efforts, and will engage them on a
multilateral and bilateral basis. Our international effort to contain
and mitigate the effects of an outbreak of pandemic influenza is a
central component of our overall strategy. In many ways, the character
and quality of the U.S. response and that of our international partners
could play a determining role in the severity of a pandemic.
The International Partnership on Avian and Pandemic Influenza,
launched by President Bush at the UN General Assembly in September
2005, stands in support of multinational organizations and national
Governments. Members of the Partnership have agreed that the following
ten principles will guide their efforts:
1. International cooperation to protect the lives and health of our
people;
2. Timely and sustained, high-level, global, political leadership
to combat avian and pandemic influenza;
3. Transparency in reporting of influenza cases in humans and in
animals caused by virus strains that have pandemic potential, to
increase understanding and preparedness, and especially to ensure rapid
and timely response to potential outbreaks;
4. Immediate sharing of epidemiological data and samples with the
World Health Organization (WHO) and the international community to
detect and characterize the nature and evolution of any outbreaks as
quickly as possible, by using, where appropriate, existing networks and
mechanisms;
5. Rapid reaction to address the first signs of accelerated
transmission of H5N1 and other highly pathogenic influenza strains, so
appropriate international and national resources can be brought to
bear;
6. Prevent and contain an incipient epidemic through capacity-
building and in-country collaboration with international partners;
7. Work in a manner complementary to and supportive of expanded
cooperation with and appropriate support of key multilateral
organizations (including WHO, Food and Agriculture Organization, and
the World Organization for Animal Health);
8. Timely coordination of bilateral and multilateral resource
allocations; dedication of domestic resources (human and financial);
improvements in public awareness; and development of economic and trade
contingency plans;
9. Increased coordination and harmonization of preparedness,
prevention, response, and containment activities among nations,
complementing domestic and regional preparedness initiatives and
encouraging, where appropriate, the development of strategic regional
initiatives; and,
10. Actions based on the best available science.
Through the Partnership and other bilateral and multilateral
initiatives, we will promote these principles and support the
development of an international capacity to prepare for, detect, and
respond to an influenza pandemic.
Following the President's National Strategy, this announcement
seeks to support selected foreign Governments through their Ministries
of Health or other responsible Ministries for human-health or public-
health emergency preparedness.
Proposals may only include program elements that fall within
designated areas under the Three Pillars of the U.S. National Strategy
assigned to the U.S. Department of Health and Human Services (HHS) as
described below. This support is meant to enhance, and not to supplant,
current influenza-surveillance activities. Proposals should build upon
infrastructure already in place. Preference will go to countries with
limited resources, where influenza surveillance is not well-
established, and
[[Page 57956]]
which have experienced outbreaks of H5N1 influenza in animals or humans
or are judged at-risk of such outbreaks by HHS and the WHO Secretariat.
Only the Ministry of Health of the Great Socialist People's Libyan Arab
Jamahiriya is eligible under this announcement.
The term ``containment'' as used in this announcement, warrants
special consideration. ``Containment'' here refers to efforts to
control the emergence of a new influenza virus with pandemic potential
and high pathogenicity that is, a new influenza strain efficiently
transmitted among humans and causes severe disease in a high proportion
of infected persons. The goal of containment would be to identify the
first outbreak with such a strain, and to apply a coordinated,
integrated, intensive public-health response to interrupt transmission
among humans. (Severe Acute Respiratory Syndrome, for example, was
ultimately contained after it spread to a number of countries.) A
principle intent of this announcement is to assist partner countries to
build capacity for identification, investigation and containment of
such a strain.
Pillar I. Preparedness and Communication
1. National Government Public-Health Preparedness Plans, Policy,
and Coordination; and,
2. Communications:
(a) Targeting health care workers (HCW); and,
(b) National Government spokespersons and risk messages.
Pillar II. Surveillance and Detection
1. Laboratory capacity and infrastructure for virologic
surveillance;
2. Epidemiology capacity and infrastructure for disease
surveillance;
3. Sentinel, laboratory-based surveillance for influenza-like
illness (ILI) and/or hospital-based surveillance for severe disease;
development or enhancement of an in-country integrated (lab and epi)
surveillance network for influenza; and
4. Comprehensive, territory-wide surveillance for cases and
clusters of suspicious respiratory and febrile illness that could
represent emerging new pandemics.
Note: Components 3 and 4 have distinct operational requirements,
but awardees must fully integrate them into one overall, multi-
disciplinary surveillance network for influenza.
Pillar III. Response and Containment
1. Local rapid-response teams; and,
2. Infection control in public health-care settings.
Pillar One
Pandemic influenza presents a massive communications challenge to
all levels of a nation's Government as well as its society, economy,
and critical infrastructure. The uncertainty of the course of a
pandemic and unknown scientific factors, as well as unforeseen and
unintended outcomes with respect to Governmental actions and statements
make this a communications-management issue of formidable proportion.
The economic and societal effects of such a pandemic could have a
significant detrimental impact on a nation and its people.
A critical component of national preparedness for an influenza
pandemic is informing the public about this potential threat and
providing a solid foundation of information upon which to base future
actions. To be effective, Governments should base these strategies on
scientifically derived risk-communications principles that are critical
before, during, and after an influenza pandemic. Effective
communication guides the public, the news media, health-care providers,
and other groups in responding appropriately to outbreak situations and
adhering to public-health measures. These guidelines must be an
integral part of a national pandemic plan as developed and coordinated
by a nation's appropriate agencies, such as Ministries of Health,
Agriculture, Trade, Information, and Tourism.
Public-health and health-care workers will be the first to observe
and report suspicious clusters of respiratory disease, and could also
be the most trusted resources of information for the populations they
serve. Therefore, these audiences must be a specific target for health-
communications marketing and strategy. Communication strategies should
include formative evaluation, message development and testing, and
summative evaluation.
In addition, these critical audiences will be integral to any
national response. Yet, worksite restrictions may hamper efforts to
receive and provide validated up-to-date information (lack of
computers, Internet access, quarantining, etc.). A mechanism for the
rapid dissemination of information both to national and District or
Provincial health-response units and international partners is
necessary.
To build trust and assure that information flows through common
channels of communication, coordination of media messages, training of
journalists and development of credible national Government
spokespeople is also recommended.
Pillar Two
One component of pandemic preparedness involves understanding the
impact annual epidemics of influenza have on a population. Data
regarding impact are critical to the development of prevention and
control measures, such as vaccination policies. Vaccination efforts are
the cornerstone of influenza prevention, and will be the primary means
of mitigating the impact of an influenza pandemic, when we have a
vaccine proven safe and effective against the pandemic strain. Another
critical area for preparedness is the ability to identify potential
human cases of novel influenza strains, so national Governments and the
international community can launch early efforts to attempt to stop
outbreaks.
The systematic collection of influenza-surveillance data over time
is necessary to monitor and track the activity of influenza virus and
disease, and is essential to understanding the impact influenza has on
a country's population. Developing influenza-surveillance networks is
critical for the rapid detection of new variants, including those with
pandemic potential, to contribute to the global disease-surveillance
system. Global collaboration, under the coordination of the Secretariat
of the World Health Organization (WHO), is a key feature of influenza
surveillance.
The WHO established an international laboratory-based surveillance
network for influenza in 1948, which currently consists of 113 National
Influenza Center (NIC) laboratories in 84 countries, and four WHO
Collaborating Centers for Reference and Research of Influenza
(including one located at the HHS Centers for Disease Control and
Prevention [CDC]). The primary purposes of the WHO network are to
detect the emergence and spread of new antigenic variants of influenza,
to use this information to update the formulation of annual human
influenza vaccine, and to provide as much warning as possible about the
next pandemic. This system provides the foundation of worldwide
influenza prevention and control, and is a critical contribution to
preserving global health security.
Monitoring of human and animal influenza viruses and providing
contributions to the global disease-surveillance system, including the
sharing of appropriate specimens and viral isolates, will assure the
data used in the WHO Secretariat's annual vaccine recommendations are
relevant to each country that participates. Increased participation in
the global surveillance system for influenza viruses will enhance each
country's ability to monitor severe respiratory illness, to develop
vaccine policy for influenza, and to help build global and regional
strategies for the prevention and control
[[Page 57957]]
of influenza in animals and humans. Monitoring the disease activity of
influenza is important to facilitate planning for the allocation of
resources, appropriate and clear communications with the public,
containment and response interventions, and outbreak investigations.
Pillar Three
In the absence of available vaccine or specific antiviral
treatment, infection control and related non-pharmaceutical public-
health interventions are the mainstay of reducing the spread and impact
of an influenza pandemic. Correct and consistent infection-control
practices should be a part of routine health-care delivery, an active
consideration in planning for pandemic influenza and other infectious-
disease outbreaks, and an integral part of outbreak response and
control. The dual goals of providing safe health-care to patients and
protecting health-care personnel while they work are critical to
maintaining a functional health-care system. Elements of health-care
related infection-control also influence community guidance for self-
protection and the prevention of infection.
The principal intent of this assistance is to support surveillance
and response, to allow for the containment of a highly pathogenic virus
transmissible among humans. A second intent is to support the
development of epidemiologic, laboratory, and related capacity to
detect, respond to, and monitor shifts in influenza viruses, as well as
in severe respiratory illness syndromes. A third intent is to help
strengthen the connection of national institutions, especially National
Influenza Centers, to more fully participate in the WHO Influenza
Program, and be more capable of sharing specimens and quality data of
the circulation of influenza viruses from throughout the country.
Measurable outcomes of the program will be in alignment with the
three Pillars of the HHS Pandemic Influenza Operational Plan and the
Pillars of the President's National Strategy for Pandemic Influenza,
the principles of the International Partnership on Avian and Pandemic
Influenza, and the following performance goal(s) for the Office of
Global Health Affairs (OGHA).
This announcement is only for non-research activities supported by
HHS, including OGHA. If an applicant proposes research activities, HHS
will not review the application. For the definition of ``research,''
please see the HHS/CDC Web site at the following Internet address:
https://www.cdc.gov/od/ads/opspoll1.htm.
Recipient Activities
The proposal may include activities under all three Pillars.
However, the application all of those activities should prioritize the
principal intent of rapidly building epidemiologic, laboratory, and
response capabilities to contain an emergent, highly pathogenic virus
transmissible among humans. Applicants should allocate a minimum of 70
percent of resources to Pillar Two activities unless they present
strong evidence that the key capacities represented in Pillar Two are
already well-established in the country, or can be made such with less
than 70 percent of the resources for which applicants have applied.
Applicants can select activities other than Pillar Two based on the
National Pandemic Plan. If applicants do not propose any activities for
one or more Pillars, they must describe a brief plan for how they will
address those activities, and must describe the funding sources to
underwrite those activities, whether national resources or financing
from an alternate partner or funding source.
Activities recipients may perform under this program are as
follows:
Pillar I Preparedness and Communication
1.1 Preparedness Plans, Policy, and Coordination
Developing a high-level, Inter-Ministerial Task Force or
working group for influenza that meets regularly with representation
from both the human- and animal-health sectors, Government Ministries,
businesses, and non-governmental organizations (NGOs); to determine
ways to improve national influenza surveillance; develop prevention and
control measures such as vaccine policy; and work on national pandemic
preparedness.
Adhering to the core principles of the International
Partnership on Avian and Pandemic Influenza (https://www.state.gov/r/pa/
prs/ps/2005/53865.htm), including transparency and rapid reporting of
cases.
Establishing a national plan, based on scientifically
valid information, for containing influenza in animals with human
pandemic potential, and for responding to a human pandemic.
Testing and executing those plans.
Committing to the timely coordination of bilateral and
multilateral resource allocations, the dedication of domestic resources
(human and financial), and the development of contingency plans.
1.2 Communications
Establishing a communications component as part of a
National Pandemic Plan, coordinated by the Ministries of Health,
Agriculture, Information, Trade, Tourism, etc., as appropriate to
accomplish the following:
Establishing a communications strategy to coordinate the
development, testing and evaluation of health information among
involved Ministries and bilateral/multilateral agencies that are
providing assistance.
Prepare public-health messages in local languages to ask
medical and public-health workers to report unusual cases of
respiratory disease to local authorities, by emphasizing that a cluster
of severe pneumonia of unknown origin anywhere in the world constitutes
a potential international emergency.
Prompt reporting of cases and clusters of human infection
with avian influenza A (H5N1) by doing the following:
[cir] Providing technical support for local-language public-health
education and outreach efforts by Ministries of Health and Agriculture,
the World Health Organization (WHO)/Headquarters, and the relevant WHO
Regional Offices;
[cir] Providing local-language training for health-care providers
in identifying patients with risk factors for disease caused by highly
pathogenic avian influenza A (H5N1); and,
[cir] Supporting public-sector field staff in Districts and
Provinces in detecting and reporting suspected cases of highly
pathogenic avian influenza.
Develop public-health materials in local languages for use
in community-based educational campaigns that inform people about
infection control and public-health containment (or ``social
distancing'') measures (e.g., quarantine, school closures, travel
restrictions) that can control outbreaks of pandemic influenza. These
materials will also provide information about the use of proper and
safe antiviral drugs and vaccines.
[cir] Ensure these activities and messages fit together and are
consistent with inter-Ministerial Governmental social- mobilization
efforts and similar efforts funded by the U.S. Agency for International
Development (USAID) and other donors.
Develop local-language mass-media and community-outreach
programs that promote AI awareness and behavior change, if other
partners are not addressing this area consistent with the national
pandemic response plan.
[[Page 57958]]
Identify and train credible national Government
spokespeople.
Partner early with media editors and journalists, if other
partners are not addressing this area, consistent with the national
pandemic response plan, to:
[cir] Provide valid training on avian influenza to journalists and
editors.
Develop public-health materials in local languages that
inform health-care workers about infection-control measures that can
control the spread of pandemic influenza in health-care facilities and
in the workplace. These materials will also provide information about
antiviral use.
Develop health-promotion and education activities in local
languages to increase professional awareness of the need to detect each
and every case and cluster of human respiratory infection (family,
health care, or institutional) during the pandemic-alert period.
Work with the WHO Secretariat and other multilateral
organizations, existing bilateral programs, and private-sector partners
to develop workplace, community- and hospital-based health prevention,
promotion, and education activities.
Pillar II. Surveillance and Detection
2.1 Laboratory Capacity and Infrastructure
Train laboratory scientists and technicians in proper
laboratory techniques for influenza detection, typing, and sub-typing.
Install and maintain laboratory equipment and
infrastructure needed to carry out the functions of WHO-certified
National Influenza Center, if possible, or work towards the capacity to
carry out those functions.
Maintain and assure biosafety and biosecurity of targeted
laboratories according to national and international standards.
Install and maintain information-management equipment for
reporting of results from influenza laboratory work, back to the sites
providing specimens, to national leaders, and to the WHO Secretariat
and other international partners.
2.2 Epidemiology Capacity and Infrastructure
Train epidemiologists at appropriate levels and sufficient
scale to be able to support multiple surveillance, outbreak
investigation and response, and disease-control activities involved in
avian and pandemic preparedness.
Establish needed information and data-management capacity
and telecommunications capacity needed for surveillance, outbreak
response, and disease control, including containment of a suspect
pandemic virus.
Establish other needed infrastructure critical to
supporting outbreak detection, response, and containment efforts.
2.3 Sentinel, Laboratory-Based Surveillance for Influenza-Like
Illnesses and/or Hospital-Based Surveillance for Severe Disease
Develop a nationwide system to collect virologic and
epidemiologic data for influenza, including appropriate samples and
viral isolates, by establishing three or more sites with good
geographic distribution throughout the country. Each site will consist
of a local laboratory and one or more public or private clinics or
hospitals from which to collect data. Each site should do the
following:
[cir] Conduct virologic and epidemiologic surveillance for
influenza by collecting information, including appropriate samples and
specimens for virus isolation year-round;
[cir] Have lab capacity for performing the isolation and typing of
influenza viruses; or at least molecular technology for identification;
[cir] Collect information on influenza-like illnesses and/or severe
respiratory disease at each site by building on information already
available. Possible sources of information are the following: (1)
Recording visits by patients with influenza-like-illness to physicians
or public or private primary-care clinics or hospitals, based on a
standard case definition; (2) Monitoring hospital admissions for severe
respiratory illness and pneumonia, based on a standard case definition.
The sites should collect patient information, such as age, patient
history and other relevant information;
[cir] Collect a subset of at least 10 (and preferably up to 25)
specimens from the patient populations under surveillance that exhibit
febrile, acute upper-respiratory illness weekly during the period of
surveillance by using a standard case definition (preferably one
established by the WHO Secretariat) and submit them to the local
laboratory for the site;
[cir] During unusual outbreaks of influenza, such as outbreaks with
unusual epidemiologic characteristics, or those related to infections
by highly pathogenic avian or other animal influenza viruses; collect
epidemiologic information to characterize the outbreak; and collect
additional samples for viral isolation, including tissue samples, if
appropriate; and submittal to the site laboratory. Report the outbreak
to the National Influenza Center for further transmittal to one or more
of the WHO-designated Collaborating Centers for Influenza;
[cir] Prepare and provide regular weekly reports on the
epidemiologic information collected (influenza-like-illness and/or
severe respiratory illness) to the local laboratory and to the National
Influenza Center for further transmittal to one or more of the WHO-
designated Collaborating Centers for Influenza;
[cir] If proper biosafety conditions exist, perform viral isolation
for influenza viruses, either in tissue culture or in eggs, type
positive isolates for influenza A and B, and, if possible, subtype
influenza viruses;
[cir] Store original clinical materials at -70 degrees celsius,
until the beginning of the next influenza season; and,
[cir] Submit viral isolates to the National Influenza Center within
the country on at least a monthly basis for more complete analysis.
Each WHO-certified National Influenza Center also will be
responsible for and commit to performing the following activities:
[cir] Performing preliminary antigenic and, if possible, genetic
characterization on the virus isolates submitted from the laboratories
in the surveillance sites (including those isolates grown at the NIC);
[cir] Send, as quickly as possible, representative influenza virus
isolates to one of the four WHO Collaborating Centers for Influenza,
including any low-reacting viruses, as tested by using the WHO reagent
kit, each month during the period of surveillance and more frequently,
if possible;
[cir] If any viruses are unsubtypable as tested by using the WHO
kit, alert the WHO Secretariat and send the virus isolate to one of the
four WHO Collaborating Centers for Influenza immediately;
[cir] During the period of surveillance, provide weekly influenza-
surveillance information, preferably electronically to the WHO
Secretariat through FluNet;
[cir] Provide an annual national summary on influenza activity,
virological information, and other relevant information on influenza to
the WHO Secretariat and the WHO Collaborating Center for Influenza at
HHS/CDC;
[cir] Provide technical expertise and training to support the
surveillance sites and laboratories in the national network in
developing the capacity to type and subtype viruses and when feasible
to identify avian influenza viruses by molecular techniques; and
provide reagents to national public-health laboratories as able;
[[Page 57959]]
[cir] Establish the capacity to identify avian influenza viruses in
specimens collected from suspect cases using molecular diagnostic
techniques;
[cir] Provide support for human-health diagnostic laboratories in
your network by giving assistance in the development and implementation
of rapid laboratory diagnostics protocols and methods, and to establish
objectives for rapid screening; and,
[cir] Establish linkages with surveillance systems that detect
influenza viruses in animal populations and with national Government
authorities responsible for animal health.
Foreign Governments that apply for funding through this
announcement should play a substantial role in the development and
support of the influenza-surveillance network in their countries, by
committing to the following:
[cir] Timely and sustained high-level political leadership to
combat avian and novel influenza strains;
[cir] Complete transparency in the reporting of influenza cases in
humans and animals caused by virus strains that have pandemic
potential;
[cir] Timely sharing of influenza-surveillance information with the
WHO Global Influenza Surveillance network by facilitating the regular
exchange of information and virus samples with one of the four WHO
Collaborating Centers for Influenza; and,
[cir] Providing continued support for influenza activities within
the country and developing a plan for increased participation in the
global influenza surveillance network over a five-year period.
2.4 Comprehensive, National Surveillance for Clusters and Cases of
Severe Respiratory and Febrile Syndromes That Might Represent Emergent
Cases From a Highly Pathogenic Influenza Virus of Pandemic Potential
Establish early-warning networks, adapt international case
definitions, and implement standards for laboratory diagnostics of
human and animal samples.
Strengthen early-warning systems for reporting human cases
of infection with influenza A (H5N1) by:
[cir] Initiating or enhancing Participation in the WHO Global
Outbreak Alert and Response Network (GOARN) to report possible
outbreaks of highly pathogenic avian influenza in humans and the WHO
Global Influenza Surveillance Network to share specimens and viruses.
Develop and establish village-based public-sector alert-
and-response surveillance systems for human cases of influenza. By
providing health education at the community level and to providers and
setting up a system for reporting of suspect cases based on a standard
case definition.
Develop a system that rapidly notifies National Government
authorities of suspect avian influenza cases and provides appropriate
samples for testing at the national level if the capacity does not
exist at a country's network site.
Establish a system to monitor for severe cases of
respiratory illness for a possible case or cluster of the H5N1 virus or
other respiratory diseases that pose a global threat.
Develop protocols and tools to investigate cases and
clusters, including the widespread dissemination of specimen collection
and transport materials, to allow rapid diagnosis.
Note: The WHO-certified National Influenza Center (NIC) within a
country can be one of the surveillance sites, and, as such, conduct
all the activities listed above under components 2.3 and 2.4.
However, component 2.4 is often the responsibility of units of
Ministries of Health other than the laboratory unit that serves as
the National Influenza Center, and Governments might need to share
resources across units and establish protocols to fulfill the
requirements of components 2.3 and 2.4. If there are two or more
NICs within a country, each NIC could participate as a site;
however, NICs within a single country should work together and place
emphasis on the addition of new surveillance sites. In addition, the
NIC(s) should act as the focal point and authority within the
country on influenza surveillance, and be the main point of
communication with the WHO Secretariat and WHO Collaborating Centers
for the rapid submittal of virus isolates and information into the
global influenza surveillance system.
Pillar III. Response and Containment
3.1 Local Rapid-Response Teams (RRT)
Develop and adopt rapid-response protocols for use in
responding quickly to credible reports of human-to-human transmission
that could indicate the beginnings of an influenza pandemic. Awardees
may carry out this action in conjunction with HHS, USAID, the WHO
Secretariat, and other donor countries.
Develop and train in-country rapid-response teams to
assess and report quickly on possible outbreaks of avian and human
influenza at the village level by accomplishing the following:
[cir] Developing national and regional rapid-response teams
deployable within 24 hours; and,
[cir] Working with GOARN to train members of response teams and
staff from Ministries of Health and Agriculture. Training topics should
include outbreak investigations, cluster investigations, case-control
investigations, and case-cohort investigations.
3.2 Infection Control
Develop local-language public-health materials, in
cooperation with HHS that inform local health-care workers and hospital
administrators in priority counties about infection-control measures to
control the spread of pandemic influenza in health-care facilities and
in workplace health facilities. The information should include guidance
about the appropriate use of antiviral drugs and vaccines.
Develop and/or field-test and evaluate culturally and
economically appropriate standards for infection-control practices and
infrastructure for international health-care settings.
Develop economical and culturally acceptable standardized
preventive practices for the routine delivery of health-care that will
be effective in prevention of health-care-associated influenza
transmission during a pandemic. (e.g., routine management standards for
febrile respiratory illnesses).
Develop and/or field-test and evaluate culturally and
economically feasible community-based practices for the prevention of
infection in community settings.
Develop a costed national plan for delivering basic
infection-control materials to and maintaining them in District and
Provincial hospitals, with guidance for distribution and use in
preparation for and during the anticipated disruptions caused by a
pandemic of influenza.
Develop, in partnership with international public-health
agencies, instructional material for print or broadcast to target
infection-control and nursing personnel in local languages to train
them in appropriate cohorting, cleaning, worker protection and the use
of protective equipment (e.g., gloves, gowns, masks, etc.).
I. Funding Opportunity Description
Authority: Sections 301(a) and 307 of the Public Health Service
Act (42 U.S.C. 241(a) and 42 U.S.C. 2421).
II. Award Information
The administrative and funding instrument to be used for this
program will be the cooperative agreement in which substantial OGHA/HHS
scientific and/or programmatic involvement is anticipated during the
performance of the project. Under the cooperative
[[Page 57960]]
agreement, OGHA/HHS will support and/or stimulate awardee activities by
working with them in a non-directive partnership role. HHS staff is
substantially involved in the program activities, above and beyond
routine monitoring. Through this cooperative agreement, HHS will
collaborate in an advisory capacity with the award recipient,
especially during the development and implementation of a mutually
agreed-upon work plan. HHS will actively participate in periodic
progress reviews and a final evaluation of the program.
Approximately $1,000,000.00 in fiscal year (FY) 2006 funds is
available to support the agreement under the Department of Defense,
Emergency Supplemental Appropriations to Address Hurricanes in the Gulf
of Mexico, and Pandemic Influenza Act, 2006 which provides funds to
combat a potential influenza pandemic both domestically and
internationally.
The anticipated start date is October 27, 2006. There will only be
one single award made from this announcement. The project period for
this agreement is for three (3) years with a budget period of 12
months.
The award recipient must comply with all HHS management
requirements for meeting participation and progress and financial
reporting for this cooperative agreement. (Please see HHS Activities
and Program Evaluation sections below.)
HHS/OS/OGHA activities for this program are as follows:
Pillar One
Organize an orientation meeting with the award recipient
to brief them on applicable U.S. Government expectations, regulations,
policies and key management requirements, as well as report formats and
contents.
Review and approve the process used by the grantee to
select key personnel and/or post-award subcontractors and/or sub
grantees to be involved in the activities performed under this
agreement.
Review and approve the grantees' annual work plan and
detailed budget.
Review and approve the grantees' monitoring and evaluation
plan, including for compliance with the performance management metrics
and systems developed for U.S. Government and HHS assistance related to
avian and pandemic influenza.
Meet or teleconference on a regular basis, as necessary,
with the grantee to assess quarterly technical and financial progress
reports and modify plans as necessary.
Meet on an annual basis with the grantee to review annual
progress report for each U.S. Government fiscal year, and to review
annual work plans and budgets for subsequent year.
Provide technical assistance, as mutually agreed upon, and
revise annually during validation of the first and subsequent annual
work plans. This could include expert technical assistance and targeted
training activities in specialized areas relevant to influenza pandemic
preparedness, containment, and mitigation.
Pillar Two
Provide technical assistance on techniques and reagents
for the identification of influenza viruses. Annually provide the WHO
reagent kit, produced and distributed by the WHO Collaborating Center
for Influenza at HHS/OGHA;
Providing epidemiological and laboratory training;
Providing technical consultation on the development of in-
country influenza-surveillance networks;
Providing confirmation of antigenic analysis and more
detailed characterization information on the influenza virus isolates
submitted to HHS/OGHA, with written reports back to the National
Influenza Center; and,
Providing technical advice on the conduct of local and
regional epidemiologic outbreak investigations.
Pillar Three
Providing technical advice and training in the development
of local rapid-response teams;
Providing technical advice for the development of policies
and capabilities for rapidly mobilizing materials from stockpiles of
pharmaceuticals and commodities to the site of an outbreak; and,
Providing technical advice and training in developing
plans for infection control.
III. Eligibility Information
1. Eligible Applicants
This is a single source, cooperative agreement with the Ministry of
Health of the Great Socialist People's Libyan Arab Jamahiriya (Libya).
On November 1, 2005, President George W. Bush announced the U.S.
National Strategy for Pandemic Influenza, and the following day
Secretary Michael O. Leavitt released the HHS Pandemic Influenza Plan.
One of the primary objectives of both documents is to leverage global
partnerships to increase preparedness and response capabilities around
the world ``with the intent of stopping, slowing or otherwise limiting
the spread of a pandemic to the United States.''\1\ Pillars Two and
Three of the National Strategy set out the clear goals of ensuring the
rapid reporting of outbreaks and containing outbreaks beyond the
borders of the United States.
---------------------------------------------------------------------------
\1\ National Strategy for Pandemic Influenza, p. 2.
---------------------------------------------------------------------------
We rely upon our international partnerships, with the United
Nations (UN); international organizations; and private, non-profit
organizations, to amplify our efforts, and will engage them on a
multilateral and bilateral basis. Our international effort to contain
and mitigate the effects of an outbreak of pandemic influenza is a
central component of our overall strategy. In many ways, the character
and quality of the U.S. response and that of our international partners
could play a determining role in the severity of a pandemic.
The International Partnership on Avian and Pandemic Influenza,
launched by President Bush at the UN General Assembly in September
2005, stands in support of multinational organizations and national
Governments. Members of the Partnership have agreed that the following
ten principles will guide their efforts:
1. International cooperation to protect the lives and health of our
people;
2. Timely and sustained, high-level, global, political leadership
to combat avian and pandemic influenza;
3. Transparency in reporting of influenza cases in humans and in
animals caused by viruses trains that have pandemic potential, to
increase understanding and preparedness, and especially to ensure rapid
and timely response to potential outbreaks;
4. Immediate sharing of epidemiological data and samples with the
World Health Organization (WHO) and the international community to
detect and characterize the nature and evolution of any outbreaks as
quickly as possible, by using, where appropriate, existing networks and
mechanisms;
5. Rapid reaction to address the first signs of accelerated
transmission of H5N1 and other highly pathogenic influenza strains, so
appropriate international and national resources can be brought to
bear;
6. Prevent and contain an incipient epidemic through capacity-
building and in-country collaboration with international partners;
7. Work in a manner complementary to and supportive of expanded
cooperation with and appropriate support of key multilateral
organizations (including the WHO, Food
[[Page 57961]]
and Agriculture Organization, and the World Organization for Animal
Health);
8. Timely coordination of bilateral and multilateral resource
allocations; dedication of domestic resources (human and financial);
improvements in public awareness; and development of economic and trade
contingency plans;
9. Increased coordination and harmonization of preparedness,
prevention, response and containment activities among nations,
complementing domestics and regional preparedness initiatives, and
encouraging where appropriate the development of strategic regional
initiatives; and,
10. Actions based on the best available science.
Through the Partnership and other bilateral and multilateral
initiatives, we will promote these principles and support the
development of an international capacity to prepare for, detect, and
respond to an influenza pandemic. Based on an overall public health
analysis for pandemic flu, Libya requires assistance in detection,
surveillance and other areas to manage and identify Avian Influenza.
Avian Influenza is a significant burden on neighboring countries of
Libya. Egypt, for example, has consistently identified the H5N1 virus
in poultry and humans resulting in human fatalities and the near
decimation of its poultry industry. Other countries proximate to Libya
which have reported human cases of H5N1 include Turkey, Iraq, and
Azerbaijan. Sharing the same bird fly-ways and trading goods daily with
many of its neighboring countries already affected by H5N1, Libya is at
heightened risk. For these reasons, eligibility for this cooperative
agreement is limited to the country of Libya.
Twenty-two years of sanctions has isolated Libya from the rest of
the world and exacerbated the seriousness of the situation within
Libya. The sanctions have prevented Libya from experiencing the
benefits of medical training in state-of-the art practice and
scientific collaborations leaving Libya vulnerable to an influenza
pandemic.
Libya recently appointed its first Minister of Health and is in the
early stages of developing a Ministry of Health. Previously, under the
General People's Committee for Health and Environment of the Great
Socialist People's Libyan Arab Jamahiriya, public health services did
not in exist. With the control and governance of public health services
now delegated to Libya's Ministry of Health, the Ministry of Health
assumes responsibility for developing and building the capacity of the
public health care system. Therefore, in accordance with the guidance
presented here, and the demand to seek Ministers of Health of countries
affected, the only eligible source for any efforts in building the
capacity of the public health care system in the country of Libya is
the Minister of Health.
2. Cost-Sharing or Matching
Although cost-sharing, matching funds, and cost participation are
not a requirement of this agreement, preference may go to organizations
that can leverage additional funds to contribute to program goals. If
applicants receive funding from other sources to underwrite the same or
similar activities, or anticipate receiving such funding in the next 12
months, they must detail how the disparate streams of financing
complement each other.
3. Other - (If Applicable)
If an applicant requests a funding amount greater than the ceiling
of the award range, HHS will consider the application non-responsive,
and it will not enter into the review process. HHS will notify the
applicant that the application did not meet the submission
requirements.
IV. Application and Submission Information
1. Address To Request Application Package:
This Cooperative Agreement project uses the Application Form HHS
Office of Public Health and Science (OPHS) OPHS-1, Revised 8/2004,
enclosed in the application packet. Many different programs funded
through the HHS Public Health Service (PHS) use this generic form. Some
parts of it are not required; applicants must fill out other sections
in a fashion specific to the program. Instructions for filling out
OPHS-1, Revised 8/2004 will be included in the application packet.
These forms are also available from the following sites by downloading
from https://egrants.osophs.dhhs.gov and clicking on Grant
Announcements, or https://www.grants.gov/; or by writing to Ms. Karen
Campbell, Director, Office of Grants Management, Office of Public
Health and Science, U.S. Department of Health and Human Services, Tower
Building, 1101 Wootton Parkway, Suite 550, Rockville, MD 20852; or by
contacting the HHS/OPHS Office of Grants Management, at 1-(240) 453-
8822. Please specify the HHS program(s) for which you are requesting an
application kit.
ADDRESSES: Application kits may be requested from, and applications
submitted to Karen Campbell, Director, Office of Grants Management,
Office of Public Health and Science (OPHS), Department of Health and
Human Services, 1101 Wootton Parkway, Suite 550, Rockville, MD 20852.
2. Content and Form of Application Submission
Application Materials
A separate budget page is required for the budget year requested.
Applicants must submit with the proposal a line-item budget (SF 424A)
with coinciding justification to support each of the budget years.
These forms will represent the full project period of Federal
assistance requested. HHS will not favorably consider proposals
submitted without a budget and justification for each budget year
requested in the application. Specific instructions for submitting a
detailed budget for this application appear in the application packet.
If additional information and/or clarification are necessary, please
contact the HHS/OPHS Office of Grants Management identified in Section
VII of this announcement.
A Project Abstract submitted on 3.5 inch floppy disk must accompany
all applications. The abstract must be typed, single-spaced, and not
exceed two pages. Reviewers and staff will refer frequently to the
information contained in the abstract, and therefore it should contain
substantive information about the proposed projects in summary form. A
list of suggested keywords and a format sheet for your use in preparing
the abstract will be included in the application packet.
A Project Narrative must accompany all grant applications. In
addition to the instructions provided in OPHS-1 (Rev 8/2004) for
project narrative, the specific guidelines for the project narrative
appear in the program guidelines. Format requirements are the same as
for the Project Abstract Section; margins should be one inch at the top
and one inch at the bottom and both sides; and typeset must be no
smaller than 12 cpi, and not reduced. Applicants should type
biographical sketches either on the appropriate form or on plain paper,
and should not exceed two pages, with publications listed limited only
to those that are directly relevant to this project.
Application Format Requirements
If applying on paper, the entire application may not exceed 80
pages in length, including theabstract, project and budget narratives,
face page,
[[Page 57962]]
attachments, any appendices and letters of commitment and support.
Applicants must number pages consecutively.
HHS/OGHA will deem as non-compliant applications submitted
electronically that exceed 80 pages when printed and will return all
non-compliant applications to the applicant without further
consideration.
(a) Number of Copies: Please submit one (1) original and two (2)
unbound copies of the application. Please do not bind or staple the
application. Application must be single- sided.
(b) Font: Please use an easily readable serif typeface, such as
Times Roman, Courier, or CG Times. Applicants must submit the text and
table portions of the application in not less than 12-point and 1.0
line spacing. HHS/OGHA might return applications that do not adhere to
12-point font requirements.
(c) Paper Size and Margins: For scanning purposes, please submit
the application on 8\1/2\'' x 11'' white paper. Margins must be at
least one (1) inch at the top, bottom, left and right of the paper.
Please left-align text.
(d) Numbering: Please number the pages of the application
sequentially from page one (face page) to the end of the application,
including charts, figures, tables, and appendices.
(e) Names: Please include the name of the applicant on each page.
(f) Section Headings: Please put all section headings flush left in
bold type.
Application Format
An application for funding must consist of the following documents
in the following order:
i. Application Face Page: Public Health Service (PHS) Application
Form OPHS-1, provided with the application package. Prepare this page
according to instructions provided in the form itself.
DUNS Number
An applicant organization is required to have a Data Universal
Numbering System (DUNS) number in order to apply for a grant from the
Federal Government. The DUNS number is a unique nine-character
identification number provided by the commercial company, Dun and
Bradstreet. There is no charge to obtain a DUNS number. Information
about obtaining a DUNS number can be found at https://www.dnb.com/
product/eupdate/requestOptions.html or call 1-866-705-5711. Please
include the DUNS number next to the OMB Approval Number on the
application face page. An application will not be reviewed without a
DUNS number.
Additionally, the applicant organization will be required to
register with the Federal Government's Central Contractor Registry
(CCR) in order to do electronic business with the Federal Government.
Information about registering with the CCR can be found at https://
www.hrsa.gov/grants/ccr.htm.
Finally, an applicant applying electronically through Grants.gov is
required to register with the Credential Provider for Grants.gov.
Information about this requirement is available at https://
www.grants.gov/CredentialProvider
An applicant applying electronically through the OPHS E-Grants
System is required to register with the provider. Information about
this requirement is available at https://egrants.osophs.dhhs.gov.
ii. Table of Contents: Provide a Table of Contents for the
remainder of the application (including appendices), with page numbers.
iii. Application Checklist: Application Form OPHS-1, provided with
the application package.
iv. Budget: Application Form OPHS-1, provided with the application
package.
v. Budget Justification: The amount of financial support (direct
costs) that an applicant is requesting from the Federal granting agency
for the first year is to be entered on the Face Sheet of Application
Form PHS 5161-1, Line 15a. The application should include funds for
electronic mail capability unless access by Internet is already
available. The amount of financial support (direct costs) entered on
the SF 424 is the amount an applicant is requesting from the Federal
granting agency for the project year.
Personnel Costs: Personnel costs should be explained by listing
each staff member who will be supported from funds, name (if possible),
position title, percent full time equivalency, annual salary, and the
exact amount requested.
Fringe Benefits: List the components that comprise the fringe
benefit rate, for example health insurance, taxes, unemployment
insurance, life insurance, retirement plan, tuition reimbursement. The
fringe benefits should be directly proportional to that portion of
personnel costs that are allocated for the project.
Travel: List travel costs according to local and long distance
travel. For local travel, the mileage rate, number of miles, reason for
travel and staff member/consumers completing the travel should be
outlined. The budget should also reflect the travel expenses associated
with participating in meetings and other proposed trainings or
workshops.
Equipment: List equipment costs and provide justification for the
need of the equipment to carry out the programs goals. Extensive
justification and a detailed status of current equipment must be
provided when requesting funds for the purchase of computers and
furniture items.
Supplies: List the items that the project will use. In this
category, separate office supplies from medical and educational
purchases. Office supplies could include paper, pencils, and the like;
medical supplies are syringes, blood tubes, plastic gloves, etc., and
educational supplies may be pamphlets and educational videotapes.
Remember, they must be listed separately.
Subcontracts: To the extent possible, all subcontract budgets and
justifications should be standardized, and contract budgets should be
presented by using the same object class categories contained in the
Standard Form 424A. Provide a clear explanation as to thepurpose of
each contract, how the costs were estimated, and the specific contract
deliverables.
Other: Put all costs that do not fit into any other category into
this category and provide an explanation of each cost in this category.
In some cases, grantee rent, utilities and insurance fall under this
category if they are not included in an approved indirect cost rate.)
vi.Staffing Plan and Personnel Requirements: An applicant must
present a staffing plan and provide a justification for the plan that
includes education and experience qualifications and rationale for the
amount of time being requested for each staff position. Position
descriptions that include the roles, responsibilities, and
qualifications of proposed project staff must be included in Appendix
B. Copies of biographical sketches for any key employed personnel that
will be assigned to work on the proposed project must be included in
Appendix C.
vii. Project Abstract: Provide a summary of the application.
Because the abstract is often distributed to provide information to the
public and Congress, please prepare this so that it is clear, accurate,
concise, and without reference to other parts of the application. It
must include a brief description of the proposed grant project
including the needs to be addressed, the proposed services, and the
population group(s) to be served.
Please place the following at the top of the abstract:
Project Title;
Applicant Name;
Address;
[[Page 57963]]
Contact Phone Numbers (Voice, Fax);
E-Mail Address; and,
Web site Address, if applicable.
The project abstract must be single-spaced and limited to two pages
in length.
viii. Program Narrative: This section provides a comprehensive
framework and description of all aspects of the proposed program. It
should be succinct, self-explanatory and well organized so that
reviewers can understand the proposed project.
Use the following section headers for the Narrative:
Introduction
This section should briefly describe the purpose of the proposed
project.
Work Plan
Describe the activities or steps that will be used to achieve each
of the activities proposed in the methodology section. Use a time line
that includes each activity and identifies responsible staff.
Resolution of Challenges
Discuss challenges that are likely to be encountered in designing
and implementing the activities described in the Work Plan, and
approaches that will be used to resolve such challenges.
Evaluation and Technical Support Capacity
Describe current experience, skills, and knowledge, including
individuals on staff, materials published, and previous work of a
similar nature.
Organizational Information
Provide information on the applicant agency's current mission and
structure, scope of current activities, and an organizational chart,
and describe how these all contribute to the ability of the
organization to conduct the program requirements and meet program
expectations.
ix. Appendices: Please provide the following items to complete the
content of the application. Please note that these are supplementary in
nature, and are not intended to be a continuation of the project
narrative. Be sure each appendix is clearly labeled.
1. Appendix A: Tables, Charts, etc.
To give further details about the proposal.
2. Appendix B: Job Descriptions for Key Personnel.
Keep each to one page in length as much as is possible. Item 6 in
the Program Narrative section of the PHS 5161-1 Form provides some
guidance on items to include in a job description.
3. Appendix C: Biographical Sketches of Key Personnel.
Include biographical sketches for persons occupying the key
positions described in Appendix B, not to exceed two pages in length.
In the event that a biographical sketch is included for an identified
individual who is not yet hired, please include a letter of commitment
from that person with the biographical sketch.
4. Appendix D: Letters of Agreement and/or Description(s) of
Proposed/Existing Contracts (project specific). Provide any documents
that describe working relationships between the applicant agency and
other agencies and programs cited in the proposal. Documents that
confirm actual or pending contractual agreements should clearly
describe the roles of the subcontractors and any deliverable. Letters
of agreements must be dated.
5. Appendix E: Project Organizational Chart.
Provide a one-page figure that depicts the organizational structure
of the project, including subcontractors and other significant
collaborators.
6. Appendix F: Other Relevant Documents.
Include here any other documents that are relevant to the
application, including letters of supports. Letters of support must be
dated.
3. Submission Dates & Times
The Office of Public Health and Science (OPHS) provides multiple
mechanisms for the submission of applications, as described in the
following sections. Applicants will receive notification via mail from
the OPHS Office of Grants Management confirming the receipt of
applications submitted using any of these mechanisms. Applications
submitted to the OPHS Office of Grants Management after the deadlines
described below will not be accepted for review. Applications which do
not conform to the requirements of the grant announcement will not be
accepted for review and will be returned to the applicant.
Applications may only be submitted electronically via the
electronic submission mechanisms specified below. Any applications
submitted via any other means of electronic communication, including
facsimile or electronic mail, will not be accepted for review. While
applications are accepted in hard copy, the use of the electronic
application submission capabilities provided by the OPHS eGrants system
or the Grants.gov Web site Portal is encouraged.
Electronic grant application submissions must be submitted no later
than 5:00 p.m. Eastern Time on the deadline date specified in the DATES
section of the announcement using one of the electronic submission
mechanisms specified below. All required hard-copy original signatures
and mail-in items must be received by the OPHS Office of Grants
Management no later that 5 p.m. Eastern Time on the next business day
after the deadline date specified in the DATES section of the
announcement.
Applications will not be considered valid until all electronic
application components, hard copy original signatures, and mail-in
items are received by the OPHS Office of Grants Management according to
the deadlines specified above. Application submissions that do not
adhere to the due date requirements will be considered late and will be
deemed ineligible.
Applicants are encouraged to initiate electronic applications early
in the application development process, and to submit early on the due
date or before. This will aid in addressing any problems with
submissions prior to the application deadline.
Electronic Submissions Via the Grants.gov Web Site Portal
The Grants.gov Web site Portal provides organizations with the
ability to submit applications for OPHS grant opportunities.
Organizations must successfully complete the necessary registration
processes in order to submit an application. Information about this
system is available on the Grants.gov Web site, https://www.grants.gov.
In addition to electronically submitted materials, applicants may
be required to submit hard copy signatures for certain Program related
forms, or original materials as required by the announcement. It is
imperative that the applicant review both the grant announcement, as
well as the application guidance provided within the Grants.gov
application package, to determine such requirements. A